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CHARACTERIZATION OF PHARMACEUTICAL MATERIALS BY
THERMAL AND ANALYTICAL METHODS
MANIK PAVAN KUMAR MAHESWARAM
ABSTRACT
Morphological and thermodynamic transitions in drugs as well as their amorphous
and crystalline content in the solid state have been distinguished by Thermal Analytical
techniques, which include dielectric analysis (DEA), differential scanning calorimetry
(DSC), and macro-photo-micrography. These techniques were used to establish a
structure vs. property relationship with the United States Pharmacopeia (USP) standard
set of active pharmaceutical ingredients (API). DEA measures and differentiates the
crystalline solid (low; 10-2 pS cm-1) and amorphous liquid (high; 106 pS cm-1) API
electrical ionic conductivity. DEA ionic conductivity cycle establishes the quantitative
amorphous/ crystalline content in the solid state at frequencies of 0.1 - 1.00 Hz and to
greater than 30o C below the melting transition as the peak melting temperature. This
describes the “activation energy method”. An Arrhenius plot, log ionic conductivity vs.
reciprocal temperature (K-1), of the pre-melt DEA transition yields frequency dependent
activation energy (Ea, J mol-1) for the complex charging in the solid state. The amorphous
content is inversely proportional to the Ea. Where, Ea for the crystalline form is higher
and lower for the amorphous form with a standard deviation of ± 2%. An alternate
technique has been established for the drugs of interest based on an obvious amorphous
and crystalline state identified by macro-photomicrography and compared to the
conductivity variations. This second “empirical method” correlates well with the
“activation energy” method. A comparison of overall average amorphous content by the
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empirical method had a linear relationship with the activation energy method with a
correlation coefficient of R2 = 0.925.
Additionally, new test protocols have been developed which describe the
temperature and material characterization calibration of thermal analyzers with
pharmaceuticals. These test protocols can be blended into a universal standard protocol
for DSC, DEA and thermomechanical analysis (TMA). While calibrating DSC, a
thermodynamic transition i.e. a change in heat flow, is marked by absorption (or release)
of energy by the calibrants; for DEA, at the melt transition temperature, an abrupt change
in DEA permittivity is observed; for TMA, at the transition temperature of the test
specimen, there is a change in dimensional stability and a measured change in the
coefficient of thermal expansion or contraction/softening is recorded. These test protocols
were accomplished based on “The ASTM standard test methods for temperature
calibration of thermal analytical methods”. The R2 correlation value of the calibrants for
known standard literature transition temperatures vs. DSC melting peak temperatures,
DEA Permittivity melting temperatures and TMA extrapolated onset-melting
temperatures was 0.999.
Next, drug salts were investigated by DEA in order to evaluate ionic conductivity
in pharmaceuticals. The ionic conductivity varied by several orders of magnitude in the
amorphous form of the drug salt. The drug salts have an enhanced DEA ionic
conductivity due to their ionic mobility of the salt component in the liquid phase. The
primary aim of this study is to investigate the thermal and electrical behavior of
pharmaceutical hydrochlorides using DEA and DSC techniques. From these analyses we
can predict the quality, stability and behavior of a drug salt. This study also provides a
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comprehensive characterization of ionic conductivity and molecular mobility (related to
tan delta in DEA) properties in pharmaceutical salts through the measurement of the
characteristic activation energies Ea (k) and Ea (τ) as well as polarization times (τ). The
typical ionic conductivity of a melted drug, i.e. the amorphous phase, is 105 pS cm-1and
for the salt it is higher than 106 pS cm-1. It is our opinion that a quality and a stable drug
salt form will have a high ionic conductivity of >105 pS cm-1. The DEA properties
described here can be further developed to estimate the storage stability or shelf life of
the drug salts by activation energies and polarization times. Salts with advantageous
properties are typically patentable as new chemical entities. Electro synthesis is suggested
for future drug development with the high ionic conductivity of the salts, >105 pS cm-1 to
aid reaction kinetics to form new complexes or modified salts.
The dielectric science developed to understand the crystalline and amorphous
components in pharmaceuticals would be validated by calorimetry, X-ray diffraction and
scanning electron microscopy. It has been established that the crystalline and amorphous
content measured by the DEA activation energy method is related to the DSC melting,
glass-transition profile as well as the crystal structure by X-ray diffraction and scanning
electron microscopic images.
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OBJECTIVES
The main objective of this thesis was to characterize the selected model drugs as
APIs using Differential Scanning Calorimetry (DSC) and Dielectric Analysis (DEA).
Then develop a structure versus property relationship. The latter process guided the
research to acquire a novel and efficient thermal analytical method for accurate and
precise quantification of crystalline and amorphous content in pharmaceutical solids
using a combined DSC and DEA Method. The electrical properties of the drugs and
nylon 6 polymers were studied using Dielectric Analysis. The physical properties of the
pharmaceutical solids were studied by employing DSC and TMA. Employing Scanning
Electron Microscopy (SEM), Powder X-ray diffraction (PXRD), and Macrophotomicrography the structural attributes of the solids (drugs) were studied. The initial
phase of this thesis was to characterize and develop new unique calibration procedures
for the pharmaceutical industry based on physical properties of pure APIs and Excipients.
This study describes the temperature and material characterization calibration of
differential scanning calorimeters, dielectric analyzers and thermomechanical analyzer
with pharmaceuticals over the temperature range of 25o C to 250o C. The theory of
dielectric behavior of complex chemicals, pharmaceuticals, and polymers was also
studied based on the multiple relaxation times, Cole-Cole plot of a Debye curve (for
single relaxation time) and The Polaron theory or the “hopping model for conduction”
and many alternative theories. These theories are used to describe the transfer of charge
between various specific localized sites within a material under the influence of an
electric field. This research was under taken as the basis for the later part of this study,
where the drugs and an excipient were carefully evaluated by these techniques (DEA,
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DSC and TMA) and the data interpreted was compared and ranked. Excipients are the
inactive pharmaceuticals that are used to make up a medication. The DEA technique is a
relative newcomer to thermal analysis in pharmaceutical field and it added a significant
amount of new characterization data. DEA uniquely measures the electrical properties of
the organic chemicals, drugs and excipients; polymers studied and revealed new physicalchemical properties, e.g., example, electrical ionic conductivity is a function of
temperature and time.
In the next phase of my study, pharmaceutical solids (drugs) and nylon 6
polymers were characterized and evaluated further for morphological and thermodynamic
transitions by the DSC and DEA instrumental methods. Nylon 6 polymers were used as
models (reference polymers) for crystalline and amorphous content. These techniques
were used successfully to establish a structure vs. property relationship with the API of
drugs. The physical and electrical properties of the drugs were determined and were used
to identify and quantify the crystalline and amorphous content in pharmaceutical solids.
The major value of this research is to develop a novel analytical protocol utilizing
dielectric analysis to define and quantify the crystalline and amorphous content in
pharmaceutical solids. These inventive techniques will give pharmaceutical scientists
new insights in how to understand the nature and behavior of the drug in the solid state as
this information is of the utmost importance in pre-formulation studies of drug
development.
Next, I studied the thermal and electrical behavior of hydrochloride salts of drug
substances using thermo-analytical methods. This analysis provides a perspective on the
use of the data from these techniques for predicting the quality, stability and behavior of
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these materials. This study is also aimed at providing a comprehensive characterization of
ionic

conductivity

and

molecular

mobility,

related

to

tan

delta

as

the

(loss factor/ permittivity) in DEA, properties in pharmaceutical salts i.e., crystalline and
amorphous forms through the measurement of the characteristic activation energies
Ea (k) and Ea (τ) as well as polarization times (τ).
Finally, this portion of the thesis is to validate the DEA characteristic properties
of an amorphous and crystalline material by: DSC, SEM, Macro-photography and PXRD.
Quinapril.HCl (Q.HCl) and Clopidogrel Hydrogen Sulfate (CHS) were selected and
prepared as model samples for amorphous characterization. These materials were
prepared by the solvent evaporation method. The DEA confirmation for Q.HCl and CHS
is based on an overlay of their DEA amorphous form 2nd run to another amorphous
sample prepared outside by the solvent evaporation method. The overlay was perfect in
the physical layout of both since they both attained the same ionic conductivity level.
Additionally, another amorphous entity (quench cooled) compared favorably with the
DEA amorphous form.
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CHAPTER I
INTRODUCTION
The chemical structure of a drug in a solution and its interaction with its receptor
determines its activity in the patient [1]. However, in order to deliver the active drug
molecule and excipients to the body in a physically stable state, i.e. typically as an oral
solid dosage form, it is necessary to formulate it as a drug product. Therefore, the
efficacy and safety of a drug product largely depends on the solid-state properties that
include physicochemical and material properties.
1.1 Solid Forms
Presently majority of the solid drugs and dosage forms are prepared from
crystalline active pharmaceutical ingredients (APIs). Solid materials can exist as either
crystalline or amorphous forms. The crystalline form is characterized by a regular
ordered crystal lattice structure, where there is no long-range order in amorphous form, as
in liquids [2]. Between amorphous and crystalline forms there can be states of partial
order, as in liquid crystals (see Figure 1.1.).
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Figure 1.1. Schematic representation of structure of a crystalline and amorphous solid [3]

Mostly, organic molecules prefer to exist in crystalline solid form. Crystalline
material is thermodynamically more stable than isolable amorphous material [2]. The
practical significance of this amorphous property is that there is energetic pressure for an
amorphous solid to recrystallize, so while selecting an amorphous form of a drug for
development must be made with this in mind.
In addition, to variations in the relative amount of molecular order in solids, there
can also be variations in the nature of the order. The classification of an organic
molecular solid and its sub classification of crystalline solid are shown in (Figure 1.2.).
The crystalline solids are divided in to polymorphs and hydrates. Different polymorphs
have the same molecular structure but the molecules are arranged differently in the
crystal lattice. The crystal lattice structures of solvates, hydrates and co-crystals are
similar and are made up of more than one type of molecule. A crystal is composed of the
API and a guest molecule in the pharmaceutical environment; solvates contain a solvent
molecule, under ambient conditions organic compounds incorporate water or solvents
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into their crystal lattice and in co-crystals the guest molecule included in the crystal
structure [2, 4].

Solid-States
Organic Molecular Solid

Amorphous

Crystalline

Polymorphs

Monotropic

Solvates/Hydrates

Enantiotropic

Reversible

Non-reversible

Figure 1.2. The classification of an organic molecular solid

The solid-state forms have different physicochemical as well as mechanical
properties. They are as follows: Packing properties (density, refractive index,
conductivity, hygroscopicity); Thermodynamic properties (Melting/Tg, enthalpy,
entropy, heat capacity, thermodynamic activity, solubility); spectroscopic properties
(Electronic, vibrational, rotational and nuclear spin); Kinetic properties (Dissolution rate,
physical and chemical stability; Surface properties (Surface energy, habit); Mechanical
properties (Hardness, tensile strength, compressibility, flow ability [5].
1.1.1 Amorphous state. During recent years the pharmaceutical scientists have
studied the amorphous state in detail and there are a few drug products that have reached
the market [6]. There is a growing interest in the amorphous state in the field of
3

pharmaceutics. For example, asthma medicine Accolate® (Zafirlukast) [7, 8]; antibiotic
Zinnat ® / Ceftin® (cefuroxime axetil) [9, 10], and ACE-inhibitor Accupro® / Accupril®
(Quinapril.HCl) [11, 12]. However, amorphous solids have poor stability, because of its
high chemical reactivity, both during manufacturing and storage often hinders the
development of amorphous drug formulations.
The significance of amorphous solids in pharmaceutical environment lies in their
useful properties, instability and common occurrence relative to corresponding crystals.
Due to the existence of polymorphism in the crystalline state, many scientists have raised
the question of occurrence of different solid-state forms in the amorphous state. This
phenomenon is called Polymorphism. A first order phase transition has to separate two
amorphous phases in order for the polymorphism to exist [13-16]. Polymorphism was
first found to exist in water and in some inorganic materials [17, 18]. There are some
evidences that small organic materials also exist as polymorphs [13-16].
Based on the molecular packing, intermolecular bonding network, or amorphous material
having local domains of different densities several theoretical models of amorphous
materials have been proposed in the literature during recent years [19]. The potential
energy differs in these regions with different packing densities. The physical and
chemical properties are significantly affected by these differences in local structure of an
amorphous material [19]. The heterogeneity nature of the amorphous state combined with
structural relaxation could explain some of the differences in the differently prepared
amorphous samples of the same drug or API.
1.1.1.1 Preparation of amorphous form. Amorphous material can be prepared
during several pharmaceutical-processing steps both unintentionally as well as

4

intentionally through different pathways (see Figure 1.3.), through a solution, a liquid, a
vapor, and a solid state [3, 4, 20].
REVIEW OF THE LITERATURE

Crystalline solid

Transition through
solution state
− Spray drying
− Freeze drying
− Salting-out
− Antisolvent
addition

Transition through
liquid state
− Cooling a melt

Transition through
vapour state
− Condensation

Transition through
solid state
− Grinding
− Compression
− Dehydration

Amorphous solid

Figure 2.

Different pathways to prepare amorphous materials.

Figure 1.3. Different pathways to prepare amorphous pharmaceutical materials [21]

1.1.1.2 Quantification of amorphous content. The determination of amorphous

Amorphous materials are prepared through a solution state by spray or freeze drying as
well as by
antisolvent
methods,
where the
formationinof the
amorphous
content
or salting-out
crystallineor content
is addition
based on
the various
differences
physical
material is based on rapid precipitation [3, 38]. In spray drying, solution is sprayed into hot
air and thebetween
solvent is
evaporatedforms.
so fastThere
that the
remain unorganized.
In freeze
properties
solids-state
aremolecules
several methods
to quantify crystalline
drying the solution is rapidly frozen and the solvent is sublimed in low temperature and
pressure.
As thecontent
solvent in
is removed
the solute
molecules
remain
in the unordered structure
and
amorphous
pharmaceutical
solids
(See Figure
1.4.).
they were frozen in. The same phenomenon is also involved in preparation of amorphous
material through vapour state, if the condensation of the material from vapour state to solid
state occurs fast enough, the molecules remain unorganized.
The fourth pathway to prepare amorphous material is through mechanical activation.
The process varies from the two previous methods. In solid-state transition, the amorphous
state is formed through the disruption of the crystal lattice for example during milling and
dehydration [53]. The amorphous solid is formed, when the amount of crystal defects
accumulates gradually above a critical level. Therefore, the amorphous form is more likely to
possess some memory of the long-range order of the original polymorph and to have some
seeds or nuclei of the original polymorph left [50, 54, 55]. Cryogrinding of piroxicam forms I
and II led to X-ray amorphous materials that had similar short-range orders but differed in
the residual long-range order [54]. This memory of the original polymorph can have an
influence on the stability as well as dissolution behaviour of the amorphous sample. This was
observed, when amorphous indomethacin (IMC) was prepared by cryogrinding from both and -IMC [55, 56].

2.4 Process induced changes in amorphicity or crystallinity
In addition to the methods used to deliberately prepare amorphous materials, amorphous
5
material is often created unintentionally during several pharmaceutical processes, such as
milling, compression and drying (Fig. 3) [38, 57, 58]. However, the change in crystallinity can
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Figure 1.4. Comprehensive Characterization of Various Quantification Techniques [22]
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CHAPTER II
INSTRUMENTS AND METHODS
Thermal analysis is the term used to describe the analytical techniques that
measure the physical and chemical properties of the sample as function of temperature or
time. Some of the most important thermal analysis includes Differential Thermal
Analysis (DTA), Differential Scanning Calorimetry (DSC), Thermogravimetry (TG),
Thermomechanical Analysis (TMA), Dynamic Mechanical Thermal Analysis (DMA),
and Dielectric Thermal Analysis (DEA).
2.1 Theory of Dielectric Analysis (DEA) Operation
2.1.1 Instrument. The DEA technique is relative newcomer to the thermal
analysis field. It can be used to determine the dielectric properties of a material i.e.,
mobility of an ions and dipoles of a material as a function of time, temperature, and
frequency. Dielectric instrument

(Figure 2.1. Dielectric Analyzer TA 2970) measures

two fundamental electrical characteristics of a material.
•

Capacitive (insulating) nature, which represents its ability to store electric
charge

•

Conductive nature, which represents its ability to transfer electric charge
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These electrical properties are important in themselves but have even more
significance when they are correlated to activity on a molecular level [1-3]. This
correlation allows you to probe the physical and chemical structure, process behavior,
and molecular mobility (relaxations) of pharmaceutical materials, chemicals, polymers
and composites [3-5].

Figure 2.1. Dielectric Analyzer TA 2970 Instrument

Some uses of dielectric analysis are as follows:
•

Surface properties versus bulk properties

•

Frequency dependence of thermal transitions

•

Frequency-dependent transitions at a constant temperature

•

Influence of Crystallinity or amorphicity

•

Activation energies for transitions

•

Storage stability information

•

Identification of multiple phases

•

Change in properties due to exposure to a given environment (oxidation,
thermal breakdown) [3,4]
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2.1.2 Principle. In dielectric analysis, a sample is placed on a single surface gold
ceramic inter-digitated electrode (see Figure 2.2.) when an alternating (sinusoidal
voltage) electric field is applied. This voltage polarizes the sample, causing an oscillation
of the molecules at the same frequency as the electric field but has a phase angle (or
phase shift) δ. This phase angle shift is measured by comparing the applied voltage to the
measured current (see Figure 2.3.) [4, 5]. The measured induced current is separated into
capacitive (ε") and conductive (ε!) components via the relationships shown in (Figure
2.4.). The ratio of ε!/ε" is known as the loss tangent (tanδ).
Capacitance (C) and conductance (1/R) are calculated using the following equations:
C (farads) =

!!"#$%&"'

1/R (mhos) =

!!""#$%&

x

!!"#$%&"'
!!""#$%&

!"#!!

(1)

!!"

x cos δ

(2)

Where:
R = resistance (ohms)
I = measured current (amps). V = applied voltage (volts)
f = applied frequency (Hz)
! = Phase angle shift
! = Angular frequency, 2!"(rad/sec) [4, 5]

Figure 2.2. Single surface gold ceramic
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Figure 2.3. Applied Voltage/ Current Response

Figure 2.4. Calculations of Capacitive and Conductive Components

12

The current can be measured by using the current to charge a load capacitor and then
measure the voltage across the capacitor [4, 5].
Measurements of capacitance and conductance of material are used to calculate
the following variables over wide range of frequencies, which provide valuable
information about molecular motion [5, 6]:
Permittivity (ε", real part), which is proportional to capacitance and

•

measures the alignment of dipoles (molecular groups) in the electric field.
Loss factor (ε!, imaginary part) is proportional to conductance or ion

•

conductivity and represents the energy required aligning dipoles and
moving molecular groups or ions.
Complex dielectric constant (ε*) consists of both the “real” (permittivity)

•

and the “imaginary” (loss factor) parts: ε* = ε"- iε!
A chemical bond that has an unbalanced distribution of charge in a molecule is a dipole.
One part is partially positive and the other is partially negative in a dipole. In the absence
of an applied electric field permanent dipoles exist, due to the differences in the electronegativity of the bonded atoms (e.g., carbonyl group, cyano group). An applied electric
field creates induced dipoles, which causes redistribution of electrons shared between the
bonded atoms with similar electro-negativity. The orientation process requires a
characteristic time, called the dipole or molecular relaxation time and denoted by!! [5, 6].
For Single surface and parallel plate electrodes, ε"and ε!can be calculated as
follows:
!"

ε"= !!!

(3)

!

!

ε! = !"!!"#

(4)

!
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Where:
C = capacitance (farads)
A = electrode plate area
d= plate spacing
R = resistance (ohms) [conductance = 1/R]
f = frequency (Hz)
εo= absolute permittivity of free space (equal to 8.85 x 10-12 F m -1)
Debye developed an orientation mechanism assuming a single dipole or a single
molecular relaxation time (!! ) for all the molecules [7]. The classic Debye equations for
ε"and ε!are as follows:
! !!

!
!
ε′ = ! ε! + !! !"!!

!

(5)

!

Where: ε! = unrelaxed permittivity due to induced dipoles. ε! = relaxed permittivity.
!! !!!
=
!! !"!!! !

ε!! = ! ε! +

Permittivity due to alignment of dipoles
!! !!! !"!!!

(6)

!! !"!!! !

to account for conductivity, can be written as:
ε!! = !

!! !!! !!!"!
!! !!!"! !

!

+ ! !!"!

(7)

!

Where:
!! !!! !!!"!
!! !!!"! !
!
!"!!!

=!Dipole loss factor term

= Ionic conduction term

! = Ionic conductivity (mhos cm-1)
Both loss factor and permittivity are frequency and temperature dependent.
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Permittivity has low values for pharmaceutical materials, chemicals and polymers
when measurements are performed at low temperature, below thermal transitions,
because molecules are frozen in place and the dipoles cannot move to orient and align
themselves in the direction of the electric field. When dipoles are excited by moderate
frequencies, they have enough time to become oriented, and their permittivity is high
while loss factor is low. But when the frequency becomes so high that the dipoles can no
longer follow the field, the dielectric constant falls steeply and material shows dispersion.
This phenomenon is also followed by a sharp increase in dipole loss, resulting in a peak
in loss factor. It consists of two contributions: energy losses due to the orientation of
molecular dipoles, and conduction of ionic species [5, 6, 8 & 9].
The magnitude of the conductivity term relative to the dipole term can be
adjusted by changing the frequency as the frequency is in the denominator of the ionic
conduction term. At high frequency, the dipole loss factor term is dominant; at low
frequency, the ionic conduction term is dominant. Ionic conduction is not significant
until the pharmaceutical material and polymer becomes fluid (e.g., above Tg or melting
point). Therefore, ε!! represents the energy to align dipoles or move ions below and
through Tg [5]
Above Tg, ε!! can be used to calculate the bulk ionic conductivity as follows:
! = ε!! 2!"ε!

(8)

Bulk ionic conductivity can be used to follow the physical transitions in the material that
takes place during change in degree of alignment of dipoles and ion mobility. Ionic
conductivity is related to viscosity, because fluidity is identified by the ease with which
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charged ions usually present as impurities or polar constituents in drugs can migrate
through the samples [5].
The frequency dependence of ε! andε!! , can be illustrated by a preferred method Argand diagram (Known as Cole-Cole plot) [10]. Where ε!! is plotted vs. ε! taking ω as a
parameter. When the ionic conductivity!!(!) is zero, the Argand diagram corresponds to
a Debye model is a perfect semicircle with intercepts ε! and ε! on the X-axis and with a
maximum value of (ε! − ε! )/2, shown in (Figure 2.5.). The dielectric behavior of
complex chemicals or polymers quite often can be characterized by a distribution of
relaxation times rather than by a single relaxation time, leading to departure from a
perfect semicircular arc, or appearance of more than one arc of relaxation times. As !
increases, the Argand diagram exhibits a vertical line with an intercept ε! at the ε! axis.
This is due to conduction and interfacial (Maxwell-Wagner) polarization resulted from
accumulation of charges at the electrode interfaces [5, 6 & 9].

Figure 2.5. Cole-Cole plots corresponding to the Debye curve
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Practically, the observed Argand diagrams deviate from the ideal ones, due to
various reasons: ionic conductivity, electrode polarization, the existence of more than one
dipole relaxation time for most materials, thus originating a distribution of relaxation
times, causing some differences between calculated and observed results.
One of the principal difficulties associated with studying the dielectric behavior of
solid samples is lack of generally agreed interpretive model. Several empirical
corrections modify the Debye model, among these, those proposed by Cole–Cole [11],
Davidson–Cole [12] and Havriliak–Negami [13-14]. The Debye model is, in practice, if
ever applicable to solid systems, is based on the assumption of non- interacting dipoles.
Cole and Cole noted that these general features of peak in dielectric loss and dispersion in
the real part of the susceptibility are commonly observed and suggested that the
discrepancy from the Debye model was due to the existence of more than one, almost
overlapping dipole relaxation times. When one considers the physical basis of this
distribution, it is because of inhomogeneities in the solid structure such as crystal defects
or, a distribution of orientations of the molecules within that structure.
Hill and Jonscher [15] criticized this approach on the basis that the widths of the
relaxation peaks observed in practice are so great that the distribution of relaxation times
would have to be extremely wide. An alternative and equivalent approach is to consider
the dielectric behavior to be a function of the probability of charge hopping between
specific sites in a solid or material, where the peak broadening is due to a distribution of
probabilities [16-17].
The Polaron theory or the “hopping model for conduction” is used to describe the
transfer of charge between various specific localized sites within a material under the
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influence of an electric field. According to this theory a corresponding phonon field
involving polar modes accompanies the transfer of electronic charge. This composite of
the electron and the associated phonon field are treated as a quasiparticle, i.e., the
Polaron. A slow moving electron in a dielectric induced crystal interacting with the lattice
ions through long-range forces will be surrounded by a field of lattice polarization caused
by the moving electron. The charge jumps or hops discontinuously from site to site [18].
2.2 Differential Scanning Calorimetry (DSC)
DSC is by far the most popular thermal analytical technique for the
characterization of pharmaceutical solids [1]. DSC monitors the energy required to
maintain the sample and a reference at the same temperature as they are heated. The
difference in energy is recorded as a function of temperature to give a DSC scan [19].
Heat flow corresponds to transmitted power and is measured in watts (W) or (mW) [20].
2.2.1 Principle. When the sample undergoes a phase transition or transformation,
a heat difference occurs between the sample and reference. Therefore, a heat would either
flow or get absorbed depending on whether the reaction is endothermic or exothermic. If
the sample absorbs energy then the enthalpy change is called endothermic. If the sample
liberates energy then enthalpy change is said to be exothermic. By recording the
difference in the heat flow between the sample and the reference material DSC measures
the energy difference of the sample. The result of a DSC experiment is a curve of heat
Flow (W g-1) vs. temperature (o C) or vs. time (min) [21-23].
DSC measurements provide information on thermal effects, which are
characterized by an enthalpy change and by temperature range, such as melting behavior,
purity, crystallization, polymorphism, solid-solid transitions and chemical reactions.
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Since DSC also measures the specific heat capacity, a change in heat capacity such as
that occurs at glass transition can also be determined [20]. DSC is widely used in the
pharmaceutical industry to characterize APIs (Active Pharmaceutical Ingredients) and
excipients

for

purity

determination,

melting

points,

polymorphism

behavior,

crystallization, glass transition, crystalline and amorphous contents, and decomposition
temperatures and more (see Figure 2.6.) [22].

Figure 2.6. DSC profile for the amorphous form of an API

2.2.2 Types of DSC. A DSC is available in two types: Heat-flux DSC and Powercompensation DSC [24]. The principles of both techniques are outlined below.
2.2.2.1 Heat-flux DSC.

Heat-flux DSC is rather similar to DTA. The big

difference is that DTA does not allow quantitative measurements to be performed, while
heat-flux DSC, owing to the well-defined thermal resistances in the cell, is eminently
suited to this kind of measurement. (Formerly, heat-flux DSC was called quantitative
DTA).
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Figure 2.7. Schematic drawing of a heat-flux DSC cell; S: sample, R: reference [25]

Sample and reference substance are place in small crucibles and positioned on
heat-flux plate (Figure 2.7.). This plate generates a very controlled heat flow from the
furnace wall to the sample and reference of changes in the thermal resistance of the
sample is eliminated. In this way, enthalpy changes in the sample can be measured
accurately.
2.2.2.2 Power-compensation DSC. Here, in contrast to heat-flux DSC, sample and
reference are completely isolated from each other (Figure 2.8.). Both, the sample crucible
and the reference crucible have their own heating element and temperature-sensing
element. With the aid of a temperature programmer, both sample and reference are heated
and always controlled to have the same temperature. As soon as changes in the sample
occur, extra (in the case of an endothermic reaction) or less (with an exothermic reaction)
heat will be needed to maintain the set-heating rate. With the aid of special electronic
circuitry, extra (or less) power is now sent to the sample holder in order to keep the
temperature difference zero [26]. In this way, power and consequently heat flow and the
enthalpy changes are measured.
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Figure 2.8. Schematic drawing of a power-compensation DSC cell: (Red) sample pan and (Blue) reference pan [27]

Heat-flux and power-compensation DSC instruments in their modern form
constitute very sensitive pieces of equipment, having the capacity to measure heat flow of
the order of micro Watts. This feature makes the applicability of the technique almost
unlimited: every physical change or chemical reaction takes place with a change of the
enthalpy and consequently absorption or release heat [28].
A characteristic DSC curve of an amorphous form of an API is shown in Figure.
6. The temperature, is always, plotted on the x-axis and Heat Flow is plotted on y-axis. In
this case a change in the specific heat leads to the baseline shift at about 61o C and
corresponds to a glass transition. The first peak corresponds to an exothermic
crystallization and the second peak to the endothermic melting of the substance (an API).
According to the standards of the ICTA (International Confederation for Thermal
Analysis), endothermic peak are plotted downward and exothermic peak upward.
According to DIN (Deutsche Industrie Norm) standard 51005, endothermic peaks are
plotted upward. Normally, every curve carries an indication of its mode or presentation.
2.2.3 Applications. There are a very large number and variety of applications of
DTA and DSC. The applications may be divided roughly into two categories [26]:
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1.

Physical changes and measurements, such as melting, crystalline phase
changes, changes in liquid and liquid crystalline states and in polymers,
phase diagrams, heat capacity, and glass transitions, thermal conductivity
and diffusivity and emissivity.

2.

Chemical reactions such as dehydration, decompositions, polymer curing,
glass formation and oxidative attack.

The numerous applications for DSC have been clearly cited in a number of reviews and
research articles [26-28].
2.3 X-ray Powder Diffractometry (PXRD)
2.3.1 Introduction. Diffraction techniques are perhaps the most definitive method
of detecting and quantifying molecular order in any system. An x-ray diffraction study
requires a clear understanding of the crystallographic structure, chemical composition,
physical properties of solid, metals, films and other polymeric materials present in a
given sample. It is a widely used in chemistry, material science, biology, geology and
environmental science, forensic science, polymer science and pharmaceutical sciences.
Other diffraction techniques that have been used to study order in pharmaceutical systems
are as follows: conventional, wide-angle and small-angle diffraction techniques [29-30].
Conventional X-ray powder diffraction, also known as PXRD (see Figure 2.9.) can be
used to quantify non-crystalline material and by controlling the temperature and
environment it can also be used to follow the kinetic phase transformation. Small-angle
X-ray diffraction technique measurements have been used to study the subtle structural
changes in polymers. Although, these methods only “observe” molecular order, and the
disorder in the system is predicted by the absence of the order [31]. PXRD is a rapid
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analytical technique primarily used for phase identification of a crystalline material and
can provide information on unit cell dimensions. Crystalline organic solids are made up
of molecules that are packed or ordered in a specific arrangement. This molecular
arrangement is defined as unit cell, which is the smallest repeating unit of a single crystal
[32].
X-Ray difraction (XRD) is most widely used in numerous industries for
identification of crystalinity in compound by studying their difraction pattern. Some other
specific benefits of XRD are listed below.
•

Single phase materials in several samples such as chemicals, ceramics,
polymers, etc., are identified.

•

Determination of polymorphs.

•

Evaluating amorphous and crystalliine content in pharmaceuticals or other
chemicals.

•

Recognition of multiple phases in samples like rocks, minerals, meltas,
etc,.

•

Quantitative determination of different phases is possible by advanced
technique called PXRD, which different phases by calculating peak ratios.

In order to interpret the data obtained from XRD you need to know a few basic
principles like how the X-rays interact with the sample, possible errors and the different
source. The mathamatics and physics involved in generating the monochromatic X-rays
and X-ray difracttion is not necessary.
2.3.2 Sample preparation. The most critical factor in obtainig a quality
analytical data relies on preparation of the specimen. In order to have a ideal sample
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preparation you need to have random distribution of crystals which should be less than
10µm. Specimen should be mounted such a way that there should be no crystallite.
Considering the above factors sample preparation is considered to be a significant topic.
2.3.3 Generate analytical x-rays. Experimental results are much better as we get
closer to the monochromatic beam in our X-ray beam. In X-ray difracttion of most
organic and inorganic crystals copper tubes are used. For copper the most stongest
radiation (Kα) is 1.54 angstroms. There are low energy and high energy radiations
produced by tubes. Kα1, Kα2 and Kβ are the high energy radiations of which we use Kα1
for analytical data. A monochromator or an energy selective detector is used to eliminate
Kβ, and Kα2 is electronically removed from X-ray data during processing.
2.3.4 XRD Principle. Sample is exposed to X-rays this interaction leads to
secondary wave which is produced by the cones in the sample. According to the
mathamatical equation Braggs law the produced secondary wave is related to the
interplanar spacing in the crysalline sample.
Braggs Law:
nλ = 2d sinθ

(9)

Where n is an integer
λ is the wavelenght of X-rays
d is the interplanar spacing generating the diffraction
θ is the diffraction angle
Diffraction maxima are measured along 2θ diffractometer circle for powder
samples having infinet amount randomly oriented crystal. According to Braggs law the
angle of diffraction is related to the interplanar spacing d, and the intensity of the
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diffraction is related to the strenght of those diffractions in the specimen. Electronic
detectors are used to measure and record angles and intensities of diffraction. Specialized
software is utilized to create plots of 2θ (X axis) vs. intensity (Y axis) for the sample.
Units for λ and d are measured in angstroms.

Figure 2.9. Phillips X-ray Diffractometer [29]

2.4 Scanning Electronic Microscopy (SEM)
SEM was first build by Von Ardenne in 1938 later it was developed and described
by Zworykin in 1942 [1,2]. A wide range of sample specimens can be analyzed to micro
structural scale using SEM. You can have an image 500 times greater than light
microscopy using SEM it gives a precise measurement of small objects down to 50nm.
An electron beam with high energy is employed to illuminate the specimen and produce
image on a fine scale. High-resolution images produced by SEM are used to analyze
chemical structure, identify micrographic and crystallographic orientation of many
25

materials. A back-scattered image from SEM is used to identify phase in a multi-phase
analysis.
2.4.1 Instrumentation. Electron Guns: A stable source of electron beam is
produced by electron gun. Field emission and thermionic emission are two strategies used
to produce these electrons for electron beam. In thermionic electron gun a wire or any
compound is heated to very high energies so that the electrons overcome the work
function of cathodes and escape in to the source. The cathode filament is placed close to
anode disc and maintained at a high negative voltage so that the produced electrons are
accelerated easily.
In field emission transport of electrons from the metal surface occurs as a result of
delocalization. This transport of electrons by delocalization is known as tunneling effect
[6].
2.4.1.1 Electron lenses. Magnets are used to manipulate configuration of electron
beam. Condenser and objective lens de-magnify electron image formed at crossover of
electron gun. In some cases demagnification is high as 10,000. Usually one or more
lenses are utilized in the condenser lens, which determines the current impinging on to
the sample while the final spot size is determined by objective lens.
2.4.1.2 Detectors. Types of detectors used in SEM are (1) solid state detectors, (2)
specimen current detectors, (3) scintillator photomultiplier detector, and (4) cathode
luminescence detector [4].
2.4.1.3 Image processing. There are three basic ways to process image: (1)
optical photographic method, which is a traditional method where image is printed using
lens available in the photographic enlarger. (2) Electric analog method in which the
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electric or analog is manipulated by the detection system in SEM. (3) digital image
process this is much advanced technique with better grey definition, sophisticated storage
methods and freedom from deterioration.
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2.5 Macro-Photomicrography
A Konica-Minolta DG SLR Camera with a 28-80 mm macro lens was used for
Macro- photomicrography to characterize the crystalline and amorphous materials on the
single surface interdigitated array gold electrodes, and material in the DSC pans. An
eyepiece reticule was used to calibrate the Macro-photomicrography system.
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CHAPTER III
STANDARD TEMPERATURE CALIBRATION PROTOCOLS AND MATERIAL
CHARACTERIZATION WITH PHARMACEUTICALS BY THERMAL
ANALYSIS
Manik Pavan Kumar Maheswaram
(Manuscript submitted for publication and is under review)
(Journal of Testing and Evaluation ASTM International)
3.1 Introduction
There are thousands pharmaceutical materials known today [1-3]. There is a need
for each material that is synthesized and discovered, to be tested and standardized.
Calibration typically uses metals e.g., Indium and Zinc to calibrate the three instruments
described in this study [4]. In order to make DSC, DEA and TMA more user friendly in
the pharmaceutical community, we have implemented the use of analytical grade APIs
and excipients for temperature and material characterization as well as calibration.
Calibration is performed by observing the melting transition temperature of standard
pharmaceutical materials within the temperature range of interest.

DSC is used to

determine the glass transition temperature, melting temperature, heat of fusion and heat
of crystallization of pure materials. These first and second order thermodynamic
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transitions can also be delineated using pure drug samples. DEA is typically used to
measure the ionic conductivity and dielectric properties of a broad range of materials [5].
TMA measures the dimensional variability of a solid polymer or material, and can also be
used to characterize powdered APIs [6]. To design an efficient procedure for calibration,
understanding the thermal analysis of all these instruments is crucial.
3.1.1 Differential Scanning Calorimetry. DSC is a thermal analysis technique
used to measure the changes in the heat flow of a sample, which involves exothermic or
endothermic processes, as a function of time and temperature. It is widely applicable to a
variety of materials such as pharmaceuticals, polymers, ceramics, metals, food and
inorganics etc [7-11]. DSC is a well-established tool for pharmaceutical or material
analysis, and provides information regarding melting temperatures, heats of fusion and
crystallization temperatures, glass transition, drug and excipient interaction, thermal
stability of pure materials or APIs. These properties are crucial for pre-formulation and
drug dosage design of pharmaceuticals.
The experimental variables considered while performing DSC are the sample
size, environment, heating rate and pan type (open pan, closed pan etc.). The performance
of DSC is dependent on all these experimental variables [2, 5-7]. The heat of fusion (Jg-1)
is associated with the DSC examination of the crystalline API (Run 1). The thermal
analysis curve represents a physical chemical property of the sample drug, i.e., melting.
Cooling of the active pharmaceutical ingredient sample after melting through the
crystallization yields the temperature and heat of crystallization (J g-1) and is needed to
further characterize the APIs.
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3.1.2 Dielectric analysis. DEA is a material characterization technique used to
measure quantitative thermal and dielectrical information on wide variety of materials,
which include solid, liquids, films and polymers [12]. It can be used e.g., to determine the
polymer viscosity, thermal transitions of polymers, characterization of food products and
pharmaceuticals. As DEA is a thermal analysis tool it compliments DSC by allowing a
measurement of molecular motion initiated by the A.C. electric field.
3.1.2.1 Principle of dielectric analysis. An applied sinusoidal voltage on a sample
placed on a single surface gold ceramic interdigitated electrode creates an alternating
electric field, producing polarization in the sample that oscillates at the same frequency as
the electric field. There is a phase angle shift δ measured by comparing the applied
voltage to the measured current, which is separated into capacitive (e’) and conductive
(e’’) components [13].
!

Capacitance- High frequency permittivity (e’) or dielectric constant.

!

Electrical conductivity (pS cm-1) - Loss factor (e”) x Applied frequency
(Hz) x 2π.

From known geometrical constants, such as electrode arrangement and electrode
spacing of the IDA electrode, desired electrical properties of the test sample or material
can be recorded. Such electrical properties are ionic conductivity, dielectric constant,
dielectric loss angle, dissipation factor, dipole relaxation time, permittivity (e’), loss
factor (e”) and tangent delta (e’’/e’). These properties are recorded as a function of time,
temperature and frequency during the course of the experiment by varying and measuring
these independent parameters [14-15].
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!

Permittivity (e’) is a measure of the alignment of molecular groups
(dipoles) in the electric field.

!

Loss factor (e’’) is a measure of the energy required to move the
molecular groups or ions and is proportional to ionic conductivity.

!

Tan delta is the ratio of the loss factor divided by the permittivity; Tan
delta = e’’/e’.

3.1.3 Thermomechanical Analysis. TMA is a thermal analysis technique used to
measure changes in the physical dimensions (length or volume) of a sample as a function
of temperature and time under a non-oscillatory load [6]. This technique is widely
applicable to a variety of materials such as pharmaceuticals, polymers, ceramics and
metals etc. TMA has been used in pharmaceutical analysis [17-19]. The variables
considered while performing the thermal mechanical analysis are; applied load, gas
environment, temperature range and heating rate as well as TMA probe type. The tests
are run in a heating mode at a desired heating rate and temperature range of interest.
Probe displacement profiles are subsequently analyzed in terms of coefficient of thermal
expansion, softening and melting temperatures, and glass transition temperatures.
Information obtained based on the different TMA probe types are shown in (Table 1),
and recorded as a function of temperature.
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Table 1
Types of TMA Probes and Resulting Measured Properties
TMA Probe Type

Information Obtained

Flat probe/ Light load

Coefficient of Thermal Expansion and Tg

Dilatometer

Coefficient of Thermal Expansion and Tg

Penetration probe/Significant load Softening/ Tg, Melting and creep modulus
Tension accessory

Tg, melting and cure behavior

Parallel plates

Melting, Viscosity and Gelation

Flexure accessory

Softening/ Tg and Melting

*Tg =Glass transition temperature

The focus of this study is to extend the selection of calibration materials from
metals to pharmaceuticals i.e., APIs for the three instruments described in this study.
Primarily by introducing a modified ASTM standard where the temperature is calibrated
with a current NIST (National Institute of standards and Technology) standard material in
addition to the use of APIs. Our overall focus is to calibrate the temperature axis of DSC,
DEA and TMA with the melting temperatures of APIs and excipients. These test
protocols permit inter-laboratory and intra-laboratory comparison and correlation of
instrumental temperature scale data within the pharmaceutical community, and would be
more relevant to quality control scientists in the pharmaceutical industry.
3. 2 Experimental
3.2.1 Materials. The following analytical grade >99.9 % pure APIs and an
excipient (Vanillin), within the temperature range of interest, were used in this test
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development as listed in Table 2 with Chemical Abstract Service (CAS) registry
numbers. The ASTM E928-08 “Standard Test Method for Purity by Differential
Scanning Calorimetry” was employed to verify the purity of the test specimen used in
this study [20].
Table 2
Calibration Materials and Their Transition Temperatures
Literature Transition
Chemical Abstract
Calibration Materials*

Temperatures/ °C
Service registry numbers
(Solid - Liquid)

Acetophenetidin

132 – 138

62-44-2 [21]

Acetanilide

113 – 116

103-84-4 [22]

Vanillin

81 – 83

122-33-5 [23]

Sulfa pyridine

191 – 193

144-83-2 [24]

*Available from Sigma- Aldrich®
3.2.2 Instruments. The TAI DSC 2920 was used to measure the heat flow
properties of calibration materials as a function of time and temperature. The test
specimens of desired temperature range from 25 to 250 °C were heated at a rate of 5 °C
min-1 with nitrogen gas purge of 50 mL min-1. Open or closed pans were used in this
study.
The TAI Dielectric Analyzer 2970 was used for dielectric analysis of the
calibration materials (test specimen), possessing dielectric properties that undergo solidliquid or solid-solid transition, over a wide range of frequencies from 0.1 to 1000 Hz and
temperatures from 25 to 250 °C. The test specimen was ramped at a rate of 5 °C min-1,
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nitrogen gas purge at a flow rate of 50 mL min-1 and liquid nitrogen cooling when
necessary. The single surface gold ceramic interdigitated (IDA) electrodes were utilized.
The TAI TMA 2940 was used to measure the dimensional change (µm) of the calibration
materials as a function of temperature. The test specimens, packed into a DSC aluminum
pan were studied over a desired temperature range from 25 to 250 °C and heated at a rate
of 5 °C min-1 with a nitrogen gas purge of 50 mLmin-1. Sample height was typically of
0.9 to 1.3 mm was used in the study.
3.2.3 Hazards. This test protocol involves the use of hazardous materials,
operations and instruments. It is the responsibility of the user to take care and establish
appropriate safety practice and to determine the applicability of regulatory limitations
prior to use, adaptation of ASTM method E1363 [6].
3.2.4 Sampling. Calibration materials are analyzed by all the three instruments
on “as received” basis. Since sample size is very small, care should be taken, so that the
test specimens are homogeneous and representative of the sample. While performing
DEA, the test specimen must cover the entire surface of the IDA electrode. The thickness
of the test specimen should be at least 1.5 times of the IDA electrode spacing. For DSC
and TMA sampling is done by packing the test specimen in a standard aluminum pan.
3.3 Calibration
Temperature signal from the instrument must be calibrated accurately over the
desired temperature range, to obtain consistent results from different experimental
conditions. Therefore, calibration is a basic process for any instrument in order to obtain
accurate results. Calibrate the permittivity and temperature sensors of the DEA
instrument using the procedure described by the manufacturer in the operator’s manual.
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This test protocol was performed and developed by using Standard Test Method for
temperature calibration of DSC, DEA and TMA, ASTM method E967 [4], E 2038 [5]
and E 1363 [6], respectively.
3.3.1 Experimental procedures for DSC, DEA and TMA.
•

Select the calibration material of known transition temperature listed in
table 2.

•

For DSC, weigh 10 mg of test material into a clean, dry aluminum pan.
The sample size for DEA is 20 to 40 mg. Care should be taken, so that the
test specimen covers the entire surface of the IDA electrode. Sample
height of 0.9 to 1.3 mm was used for TMA analysis.

•

Load the test material into the instrument chamber e.g., (DSC, DEA and
TMA), and purge the instrument with dry nitrogen gas (99.99% purity
purge gas) at constant flow rate of 50 ml min-1 throughout the experiment.

•

Set the initial temperature of the instrument to a value about 30°C below
the estimated transition temperature of the test material, and allow it to
equilibrate for 5 min at that temperature.

•

Initiate a temperature program at a constant heating rate of 3oCmin-1 to a
temperature 20°C above the estimated melt transition temperature of the
test material.

•

Note: When a DSC is used, run a Heat-Cool-Heat cycle for each test
material. Cool the test material at 3°Cmin-1 through the crystallization
exotherm until the baseline is re-established below the crystallization
temperature.
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•

Note: when a DEA is used, initiate the measurement of permittivity at a
test frequency of 1,000 Hz and a set of frequencies (1, 10, 100, 1000 Hz).
Record permittivity and log Permittivity, on a linear scale, as a function of
temperature

•

Record the accompanying thermal curve by using the instrument software.

•

Repeat the procedure described above for other calibration materials
chosen.

3.4 Results and Discussion
3.4.1 For DSC. At a thermodynamic transition temperature, i.e. change in heat
flow is marked by absorption (or release) of energy by the calibrants resulting in an
endothermic (or exothermic) peak in the heating (or cooling) curve is recorded.
•

From the resultant DSC thermal curve, measure the temperatures for the
desired points on the curve: Tm, Tmp, Tc, Tcp, Heat of fusion (Jg-1) and
Heat of crystallization (Jg-1) for a pure calibration material.

Tm = Extrapolated onset melt temperature
Tmp = Melting peak temperature
Tc = Extrapolated crystallization temperature
Tcp = Crystallization peak temperature
∆Hf = Heat of fusion
∆Hc = Heat of crystallization
The DSC thermal curves of Acetanilide (see Figure 3.1.), Acetophenetidin (see
Figure 3.2.) and Vanillin (see Figure 3.3.) are described respectively. These heat-coolheat plots show changes in the heat flow (W g-1) with respect to time and temperature.
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Figure 3.1. Acetanilide DSC curve showing Tmp =116.31° C, Tcp = 81.50° C; Heat of Fusion for first endothermic
peak ∆Hf = 143.9 Jg-1 and ∆Hf = 123.3 Jg-1 for second endothermic peak; Heat of Crystallization, ∆Hc= 112.1 Jg-1.

Figure 3.2. Acetophenetidin DSC curve showing Tmp =136.25° C, Tcp =126.18° C; Heat of fusion for first
endothermic peak ∆Hf=163.1 Jg-1 and ∆Hf = 152.8 Jg-1 for second endothermic peak; Heat of crystallization, ∆Hc =
151.9 Jg-1.
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Figure 3.3. Vanillin DSC curve showing Tmp = 83.08° C, Tcp = 38.33° C; Heat of fusion for first endothermic peak
∆Hf = 149.0 Jg-1 and ∆Hf = 137.0 Jg-1 for second endothermic peak; Heat of crystallization ∆Hc=116.2 Jg-1.

A summary of the DSC melting and crystallization properties of calibration
materials is cited in Table 3.
Table 3 describes the Melting peak temperatures (Tmp), Crystallization peak
temperatures (Tcp), Heat of fusion (∆Hf, Jg-1) Heat of crystallization (∆Hc J g-1) and %
Crystallinity of calibration materials evaluated by DSC.

41

Table 3
DSC Melting and Crystallization Properties of Calibration Materials
Melting peak
Temperatures/
Tmp °C

Calibration
materials

1st
Peak

2 Peak

Acetanilide

116.31

116.58

Acetophenetidin

136.25

Vanillin

Sulfapyridine

Cryst peak
Temperatures/
Tcp °C

∆Hf (J g-1)

(J g-1)

(∆Hc/∆Hf)*10
0

123

112

78

163

153

152

93

38.33

149

138

116

78

123

174

-

57

33

1st
Peak

2nd
Peak

81.50

144

136.61

126.18

83.08

82.45

192

Tg= (62)

nd

∆Hc

%
Crystallinity

Note: Tmp = Melting peak temperature. Tcp=Crystallization peak temperature.

3.4.2 For DEA. At the thermodynamic melt transition temperature, an abrupt
change in DEA permittivity is observed. The instrument records the temperature
observed for this transition.
•

From the resultant DEA thermal curve, following parameters are measured
to determine the property variation associated with the transition;
frequency, permittivity, log permittivity, temperature, derivative of
permittivity and log permittivity with respect to temperature.

•

Plot the DEA thermal curves of test specimens in the following manner:
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a)

Plot permittivity vs. temperature and first derivative of the
resultant curve
A single frequency (1000 Hz) and a set of 4 frequencies

i.e. (1,

10, 100 and1000 Hz) were used in evaluating each calibration
material.
b)

Plot log of permittivity vs. temperature and first derivative of the
resultant curve
A single frequency (1000 Hz) and a set of 4 frequencies i.e., (1, 10,
100, and 1000 Hz) were used in evaluating each test material.

c)

For both these calibration processes use the first derivative to
determine the inflection point of the original thermal curve and this
inflection point is used as first onset point. The second point is
typically above the known transition temperature on the original
thermal curve where the slope is constant.

d)

Employ the instrument software to determine the onset temperature
and the calibrated temperature.

The DEA curve of acetanilide showing the permittivity transition temperature for
a single frequency (1000 Hz) run is described in (Figure 3.4.). Figure 3.5 describes the
acetanilide derivative of permittivity transition temperature for a single frequency run
when plotted vs. temperature. Figure 3.6 describes the DEA Acetanilide curve showing
Log permittivity transition temperature at 10Hz. Figure 3.7 describes the DEA acetanilide
curve showing Derivative of log permittivity transition temperature at 1 Hz.
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Figure 3.4. DEA curve of Acetanilide showing permittivity transition temperature (114.12 °C) for single frequency
(1,000 Hz) run

Figure 3.5. DEA curve of Acetanilide showing Permittivity and Derivative of Permittivity transition temperature
(114.12 °C) for a single frequency (1000Hz) run
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Figure 3.6. DEA curve of Acetanilide showing Log permittivity and Derivative of Log permittivity transition
temperature (115.11 °C) at 10 Hz

Figure 3.7. DEA curve of Acetanilide showing Log permittivity and Derivative of Log permittivity transition
temperature (113.23 °C) at 1 Hz frequency
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A summary of frequency used i.e. (single or set of 4 frequencies); permittivity and
Log permittivity transition temperatures obtained from the DEA thermal curves of the
calibration materials are listed in Table 4: Acetanilide; Table 5: Acetophenetidin; Table
6: Vanillin; and Table 7: Sulfapyridine.
Table 4
DEA Permittivity and Log Permittivity transition temperatures of single (1000 Hz) and
set of frequencies (1, 10, 100, 1000 Hz) of Acetanilide Tmp =113-116 °C
Permittivity Transition

Log Permittivity Transition

Temperatures/ °C

Temperatures/ °C

1000 Hz

114.2

113.0

1Hz

115.6

113.3

10 Hz

115.1

113.5

100 Hz

113.9

114.0

1000 Hz

114.1

114.0

Average

114.6

113.7

Std Deviation

0.80

0.34

% Relative Error

0.70

0.26

Frequency/ Hz
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Table 5
DEA Permittivity and Log Permittivity transition temperature of single (1000 Hz) and set
of frequencies (1, 10, 100, 1000 Hz) of Acetophenetidin Tmp = 132-138 °C.
Permittivity Transition

Log Permittivity Transition

Temperatures/ °C

Temperatures/ °C

1000 Hz

131.0

131.0

1 Hz

132.5

132.3

10 Hz

132.5

132.7

100 Hz

132.6

132.5

1000 Hz

132.7

132.7

Average

132.6

132.6

Std Deviation

0.09

0.23

% Relative Error

0.66

0.17

Frequency/ Hz
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Table 6
DEA Permittivity and Log Permittivity transition temperature of single (1000 Hz) and set
of frequencies (1, 10, 100, 1000 Hz) of Vanillin Tmp = 81- 83 °C
Permittivity Transition

Log Permittivity Transition

Temperatures/ °C

Temperatures/ °C

1000 Hz

81.0

80.9

1 Hz

82.3

80.8

10 Hz

82.0

80.9

100 Hz

81.3

80.8

1000 Hz

81.0

80.9

Average

81.5

80.7

Std Deviation

0.90

0.18

% Relative Error

1.09

0.22

Frequency/ Hz
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Table 7
DEA Permittivity and Log Permittivity transition temperature of single (1000 Hz) and set
of frequencies (1, 10, 100, 1000 Hz) of Sulfapyridine Tmp = 191-193° C.
Permittivity Transition

Log Permittivity Transition

Temperatures/ °C

Temperatures/ °C

1000 Hz

192.0

191.0

1 Hz

192.7

191.5

10 Hz

192.8

191.0

100 Hz

191.3

190.8

1000 Hz

191.0

191.4

Average

191.9

191.1

Std Deviation

0.9

0.35

% Relative Error

0.47

0.18

Frequency/ Hz

3.4.3 For TMA. At the transition temperature of the test specimen, there is a
change in dimensional variability and the instrument records a measured change in the
coefficient of thermal expansion.
•

From the TMA thermal curve recorded, extrapolated onset temperature is
measured. This is calculated by extending the pre-transition portion of the
curve which to the point of intersection with a line drawn tangent to the
steepest portion of the curve which describes the probe displacement [6].

49

The thermal curves of Acetanilide (see Figure 3.8.) and Acetophenetidin (see
Figure 3.9.), and Vanillin (see Figure 3.10.) recorded by the instrument are described
showing the extrapolated onset melting temperature.

Figure 3.8. TMA of Acetanilide curve showing the extrapolated onset melt temperature (115.51° C).

Figure 3.9. TMA of Acetophenetidin curve showing extrapolated onset melt temperature (134.27° C)
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Figure 3.10. TMA of Vanillin curve showing extrapolated onset melt temperature (83.46° C)

A summary of TMA observed extrapolated onset temperatures of calibration materials
and literature transition temperatures are cited in Table 8.
Table 8
Summary of TMA extrapolated onset temperatures of calibration materials and literature
transition temperatures
TMA
Literature Transition
Calibration Materials*

Extrapolated Onset
Temperatures/ °C
Temperatures/ °C

Acetophenetidin

134.27

132 - 138

Acetanilide

115.51

113 -116

Vanillin

83.46

81-83

Sulfapyridine

192.78

191-193
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A summary of DSC, DEA and TMA melting temperatures for the calibrants
(API’s) studied vs. the standard literature melting temperatures values are given in Table
9.
Table 9
Summary of DSC, DEA and TMA Results
DSC Melting Peak
Literature

DEA Transition

TMA

Temperatures/ °C

Extrapolated

Temperatures/
Calibration

Transition

Materials*

Temperatures

Tmp °C
Onset

1st

2nd

Permit

Log

Peak

Peak

-tivity

Permittivity

/ °C

Temp/ °C

Acetophenetidin

132- 138

136.25

136.61

133.6

132.6

134.27

Acetanilide

113 – 116

116.31

116.58

114.6

113.7

115.51

Sulfapyridine

191 – 193

192

Tg= 62

191.9

191.1

192.78

Vanillin

81 – 83

83.08

82.45

81.5

80.7

84.46

*Available from Sigma Aldrich®, **CAS=Chemistry Abstract Service registry number.

Figure 3.11. A correlation graph of Standard Literature Transition Temperatures vs. Average of DSC, DEA & TMA
Melting Transition Temperatures of calibration Materials
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3.5 Conclusions
Statistical analysis of the results from the three methods (DSC, DEA and TMA)
indicates a high correlation with known literature values. Acetanilide, Acetophenetidin
and Sulfapyridine were quality API standards for calibration. Vanillin is a quality
excipient calibrant. The three drugs plus the excipient, studied for this standard protocol
present outstanding list of viable temperature standards. Their observed melting transition
temperature best correlates with the known literature transition temperature values. All,
but Sulfapyridine, yielded melting -crystallization - melting properties that enhance the
overall characterization of those drugs. The Tg, on the 2nd heat cycle, of Sulfapyridine at
62oC supplied additional important thermal characterization data. Permittivity is the most
appropriate property to calibrate the temperature of DEA as it deals only with dipole
variations. The ionic conductivity, though an interesting material property, is a function
of multiple properties, that are dipolar and ionic. The R2 correlation value for known
standard literature temperatures vs. DEA permittivity melting temperature for of single
(1000 Hz) and set of frequencies (1, 10, 100, 1000 Hz) was 0.99. The R2 correlation
value for known standard literature temperatures vs. TMA extrapolated onset
temperatures was 0.999. The R2 correlation value for known standard literature
temperatures value vs. DSC melting peak temperatures was 0.999. The average melting
temperature (Tm) for DSC, DEA and TMA correlated with the melting temperatures
(Tm) of the known literature values with an R2 of 0.999. (See Figure 3.11.) It is our quest
to infuse these new ASTM type standard test protocols into the pharmaceutical industry
for drug pre-formulation and dosage design of pharmaceuticals. These new
pharmaceutical based test protocols, permit inter-laboratory comparison and intra-

53

laboratory correlation of instrumental temperature scale data within the pharmaceutical
community, and will be implemented in our chemical pharmaceutical research.
The following ASTM methods were also reviewed in the course of preparing this
text:
•

E794 Standard Test Method for Melting and Crystallization Temperatures
by Thermal Analysis [25].

•

E473 Standard Terminology Relating to Thermal Analysis [26].

•

E691 Standard Practice for Conducting an Inter-laboratory Study to
Determine the Precision of a Test Method [27].

•

E1325-02 Standard Terminology Relating to Design of Experiments [28].
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CHAPTER IV
CHARACTERIZATION OF CRYSTALLINE AND AMORPHOUS CONTENT IN
PHARMACEUTICAL SOLIDS BY DIELECTRIC THERMAL ANALYSIS
4.1 Introduction
Riga et al. studied the extensive applications of dielectric analysis (DEA)
including states of matter as amorphous/crystalline. They characterized drugs, excipients,
transdermal patches, carbohydrates, proteins, amino acids, motor oil dispersants and
surfactants as well as electro rheological fluids using A.C. electrical properties over a
wide range of frequencies [1]. The importance of the amorphous state when studying
bioavailability, dissolution, and the development of poorly water-soluble APIs has grown
significantly over the recent years [2, 3]. There are two forms of solids: glassy and
crystalline forms [4]. Glassy forms or amorphous solid forms generally exist in a variety
of industrial fields or products, such as polymers and plastics, textiles, foods and
pharmaceuticals, and in the manufacture of semiconductors, ceramics, metals and optical
materials [2, 3]. With reference to a crystalline solid, an amorphous solid can be defined
as a substance with short-range molecular order; in contrast a crystalline solid has longrange order [2]. For this reason, some amorphous forms are considered as liquids
although they can solidify by the removal of thermal energy or a solvent in a way that
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avoids crystallization [5]. In pharmaceutical research, the amorphous form of a
pharmaceutical solid has been the most important aspect of drug development. The
significance of amorphous solids is presently ever-increasing due to their value to the
pre-clinical formulation scientists and in general to the pharmaceutical industry due to
various advantages [3, 6, 7]: (i) a continuous increase in the development of a number of
insoluble APIs; these glassy drug compounds are unique based on their methods of
production and screening [8], (ii) The growing attention in regulatory evaluation and
distinct economic aspects of pharmaceutical solids development [9], and (iii) The
different polymorphs of APIs including the amorphous forms have different
interconvertible physical and chemical properties [10] which exhibit different solubility
and compressibility characteristics. Processing of an amorphous drug substance is
relatively simple, and easy when compared to crystalline drug production [2, 3].
Amorphous forms can be produced by a variety of pharmaceutical techniques,
such as granulation, compaction, freeze & spray drying, melt-quench cooling, and solvent
evaporation method. These amorphous forms can be used for better solubility, dissolution
and bioavailability [6, 11, 12]. The amorphous phase has higher energy with higher
chemical reactivity and generally is less stable both physically and chemically than the
corresponding crystalline phase. The stability of the amorphous form is the main issue
when stored at temperatures close to the glass transition temperature, (Tg). The glass
transition temperature is a key characteristic property of amorphous materials.
Quantification of the amorphous fraction of an API can be better understood by
determining the heat capacity change associated with the Tg [13]. In pharmaceuticals,
amorphous solids have several useful properties and are used as both API and excipients
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[3]. Some of the useful properties are higher water solubility, higher dissolution rate [14]
(i.e. no lattice energy, which is a thermodynamic barrier to dissolution) [15], and better
compression characteristics when compared to the crystalline forms [2, 3].
Although the amorphous form has some advantages over its crystalline
counterpart, like higher free energy, lattice disorder, higher water solubility, and
molecular mobility [6], the amorphous systems have seen limited commercialization due
to its thermodynamic instability and higher chemical reactivity [11,12, 16]. The
amorphous phase can also occur throughout the particle or solid, in the bulk or at its
surface, which can be relatively distinguished by dielectric studies [17]. As the disordered
portion is low, it’s difficult to detect [11, 12]. But these high-energy reactive portions
may cause some significant changes in drug development like: improve product
performance, high dissolution rate, decreased chemical stability, solid-solid transitions,
and recrystallization during storage [11, 18]. Because of the amorphous phase
thermodynamic instability, there can be an irreversible conversion of the metastable form
to its stable crystal form during manufacturing or in normal storage. Loss of drug
function can occur when the amorphous material transitions to another meta-stable form
resulting in, for example, a varying dissolution rate of the original crystalline form [16].
Therefore, one must find a reliable method to monitor and characterize the
degree of crystallinity and the amount of disorder in the APIs during their pre-clinical
drug development to ensure commercializable formulations [11]. To maximize the
efficiency of the amorphous material and prevent transformation of the drug during
storage, one needs to understand and characterize the kinetics of the crystallization
process, and determine quantitatively the various parameters associated with nucleation
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and crystal growth [16]. This need is based on a vigorous test method to monitor the drug
throughout its shelf life to assure product safety and quality [18]. Pharmaceutical
scientists are making an effort to develop alternative methods that are precise, reliable,
and fast, which employ small samples for determining the crystallinity or low levels of
amorphicity in the sample [12]. The degree of crystallinity methodology is extensively
used to measure the relative crystalline/amorphous content in pharmaceutical materials
[19]. Several analytical techniques currently employed in the pharmaceutical industry for
quantifying,

and/or

characterization

of

crystalline

and

amorphous

forms

of

pharmaceutical materials include: X-ray diffraction analysis (XRD), dielectric Analysis
[20], solid state-NMR [21], FT–Raman [22], FT–IR [23], modulated differential scanning
calorimetry

[24],

thermally

stimulated

current

spectroscopy

[11],

isothermal

microcalorimetry, and solution calorimetry.
Morphological and thermodynamic transitions in drugs as well as their amorphous
and crystalline content in the solid state have been initiated by thermal analytical
techniques, which include DEA and thermal mechanical analysis [24, 25]. These
techniques were used successfully to establish a structure vs. property relationship with
the API of drugs [24, 25]. The main focus of this study is to develop a novel analytical
protocol utilizing dielectric analysis to define and quantify the crystalline and amorphous
content in pharmaceutical solids. These innovative techniques will give pharmaceutical
scientists new insights in how to understand the nature and behavior of drugs in the solid
state. Pharmaceutical solids studied by these methods have led to a better understanding
of the chemistry and molecular mobility that relates to the structure of the drug. This
information is of the utmost importance during pre-formulation studies of drug
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development. DEA measures the crystalline solid and amorphous liquid API electrical
conductivity at temperatures below and above the melting temperature [13-15]. DEA
scans the electrical signals over a wide range of frequencies (e.g. 0.10 to 100,000 Hz).
The DEA ionic-dielectric conductivity is repeatable and differentiates the solid crystalline
drug with a low ionic-dielectric conductivity level (<10-1 pS cm-1) and a high ionic
dielectric conductivity level associated with the amorphous liquid (>105 pS cm-1).
Further, DEA measures changes in phase (solid to liquid) transitions, significant
variations in conductivity related to the ionic dielectric behavior of melted drugs and loss
of residual solvents as it is subjected to a periodic electric field.
Our new DEA protocols can detect the crystalline and amorphous phase
repeatedly and rapidly based on the experimental frequencies, time and temperatures.
This A.C. frequency based technique has the ability to differentiate surface vs. bulk
amorphicity [25]. Typically surface analysis is best profiled at 0.10-1.0 Hz and bulk
analysis is between 1,000 - 10,000 Hz. This methodology is quick and can summarize the
relative low levels of non-crystalline and crystalline material, thereby increasing the
sensitivity of this technique.
4.1.1 Dielectric Analysis (DEA). Dielectric analysis (DEA) is a material
characterization technique that provides scientists with quantitative thermal, rheological
and dielectric information on a wide range of materials in their various forms, which
include solid, liquids, pastes, films, polymers, and organic additives in lubricating oils
[16]. It can be used to determine the flow, thermal transitions, degree and rate of cure in
polymers, characterize food products, pharmaceutical materials, and dielectric properties
of thermoplastics, composites, as well as adhesives and coatings [1].
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As DEA is a thermal analysis tool, it is closely related to DMA (frequency
dependent dynamic mechanical analysis), which measures mechanical properties of a
material. While DSC measures heat flow through which the heat of fusion and transition
temperatures can be determined. DEA compliments DSC by allowing a measurement of
molecular motion based on its electrical properties.
The theory of a dielectric or theory of dielectric analysis may be illustrated by the
time – dependent electrical response of a sample placed on a single surface gold ceramic
inter-digitated electrode when an alternating (sinusoidal voltage) electric field is applied.
This process produces polarization within the sample, causing oscillation at the same
frequency as the electric field but with a phase angle (or phase shift) δ. This phase angle
shift can be measured by comparing the applied voltage to the measured current [1 and
24]. The current is then separated into capacitive (e’) and conductive (e’’) components.
The two fundamental characteristics of a material measured through dielectrics: as
a function of time, temperature, and sampling frequency are:
!

Capacitance = High frequency permittivity (e’) or dielectric constant.

!

Electrical conductivity (pS cm-1) = Loss factor (e”) x Applied freq (Hz)
x2π

The capacitive nature of the material allows or has an ability to store an electrical
charge and this nature dominates the electrical response at low temperatures. The
conductive nature of the material has an ability to transfer an electric charge and this
factor becomes very important when the solid material is heated above its melting
temperature to the liquid state. These electrical properties are significant since they have
been related to molecular activity, allowing for probing the chemistry, and molecular
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mobility of polymers and pharmaceutical materials. DEA reports three main electrical
signals over a wide range of frequencies (e.g. 0.10 to 100,000 Hz):
!

Permittivity (e’) is a measure of the induced dipoles and alignment of
molecular groups (dipoles) in the electric field.

!

Loss factor (e’’) is a measure of the energy required to move the
molecular groups or ions and is proportional to ion conductivity. Ionic
conductivity is associated with the viscosity of the sample because fluidity
is identified by the ease with which ionic components can migrate through
the sample under the applied electric field.

!

Tan delta is the ratio of the loss factor divided by the permittivity. Tan
delta = e’’/e’. Tan delta values are related to molecular mobility, response
time to an electric field, and are related to polarization or relaxation of
excited molecules or a measure of charge transfer properties [1, 24].

We

developed

a

novel

combined

DEA-DSC

protocol

to

evaluate

amorphous/crystalline content in pharmaceutical solids. The DSC analysis will be used in
two different protocols (a) Heat cycle only to measure the temperature range for heating
to aid DEA evaluation. (b) Heat and Cool cycle to evaluate % crystalline and %
amorphous based on the fusion and crystallization heats.
The focus of these new methods is to determine the relative amounts of
amorphous and crystalline content in APIs. Pharmaceutical scientists working on preformulation of pharmaceutical drugs as well as those developing quality control of
manufactured drugs need new information on the content of amorphous/crystalline
matter. This new knowledge is to improve quality and stability of pharmaceuticals for the
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consumer. There is a clear rationale for developing these new methods to better
understand the effects of the total chemical structure on drug treatment including
amorphicity. It is logical that electrical conductivity methods are implemented now since
we have discovered significant variations in pharmaceuticals using DEA.
4.2 Methodology
Two novel DEA protocols were developed to determining the amorphous and
crystalline content in pharmaceutical drugs. The first method is “The Empirical
Method”. It is semi-quantitative method that is based on the observed significant
electrical conductivity difference between the amorphous liquid (107 pS cm-1) and
crystalline solid (10-2 pS cm-1). The second method is the “Activation Energy Method”
and is more quantitative in nature. In this method the Activation Energy, Ea (J mol-1), is
calculated from the DEA ionic conductivity. It is based on the fact that the relative Ea for
the electrical reactivity (charging or charge transport) in the solid state of the amorphous
phase is higher and conversely the Ea is lower (typically 30 -110 J.mol-1) and the
electrical reactivity of the solid state for crystalline phase is low and conversely the Ea is
higher (typically 1,200-2,000 J mol-1).
4.2.1 Empirical method protocol. The empirical method to determine crystalline
and amorphous content in pharmaceutical solids is as follows: First, a pure drug (100%
crystalline) similar to the drug with unknown content is examined by DEA as a standard.
For the pure drug prepared by the pharmaceutical company the % content before the
melting temperature is 99.99-100% crystalline and with complete melt it is 100%
amorphous in the liquid phase. Then, DEA re-run of the sample is performed to analyze
the drug with the unknown amorphous/crystalline content. A combined DEA model plot
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for the % content of an unknown drug and the pure drug is shown in the graphical
representation (Fig.1) as log ionic conductivity vs. temperature. Next, a temperature, Ts,
is selected ≤ 30 to 50o C below the melting temperature (Tm) of the drug from the
overlayed DSC curve. Then, the linear distance (Δ3) in millimeters of log ionic
conductivity on the y- axis is measured from 100% solid crystalline line (point X) to the
100% amorphous line (point Z) at the selected temperature Ts. The 100% amorphous or
liquid region is a hypothetical region and the 100% amorphous line is obtained by
extrapolating the liquid region log ionic conductivity of the DEA plot. Next, the linear
distance (Δ2) in millimeters of log ionic conductivity on the y- axis is measured from the
semicrystalline line (point Y) to the 100% amorphous line (point Z)) and (Δ1) in
millimeters from 100% solid crystalline line (point X) to semicrystalline line (point Y)) at
the temperature Ts are measured. In the semicrystalline region the ratio of amorphous to
crystalline content is not known.
The linear log conductivity distance in millimeters is a measure from the
crystalline phase to the amorphous phase, which is equated to 100%. The Amorphous and
crystalline contents can be calculated from the following equations and Figure 4.11.
% Amorphous = ∆1/∆3 x 100
% Crystalline = ∆2 /∆3 x 100
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Figure 4.1. Graphical representation of DEA Empirical method

4.2.2 Activation energy method. A second method was developed based on a
measurement of a DEA Activation Energy Ea (J mol-1) to determine the amorphous and
crystalline content in drugs by dielectric analysis. Sharma and Yashonath [26]
investigated ionic transport in a variety of inorganic amorphous glasses (solids). They
observed a strong correlation between ionic conductivity and activation energy. Further,
they found that higher conductivity is associated with lower activation energies and lower
conductivity is associated with higher activation energies. Their results suggest that there
is a strong relation between microscopic structure of the amorphous solid, ionic
conductivity and activation energy [26].

67

The Ea (J mol-1) calculation is more quantitative and is based on the relative
activation energy for the electrical reactivity (charging or charge transport) in the solid
state. The amorphous phase reactivity is higher (ca. 107 pS cm-1) and conversely the Ea is
lower (frequency at 1 or 5 Hz typically: 60-200 J mol-1) measured as the slope of the log
ionic conductivity vs. reciprocal temperature (K-1) of an Arrhenius plot and as a function
of frequency (Hz). The reactivity and conductivity (typically 10-2 pS cm-1) of the solidstate crystalline phase is lower and conversely the Ea is higher (typically measured by
DEA at a frequency of 1 or 5 Hz: 1,200-2,000 J mol-1), also measured by DEA
conductivity vs. reciprocal temperature (K-1) [27 - 29].
4.2.2.1 Activation Energy Ea (J mol-1) Protocol.
1.

Record a DEA curve of a pharmaceutical solid sample at a heating rate of
10 oCmin-1 in a nitrogen flow of 60 mL min-1; a sample size of 20 mg.
Heat to 20-30o C above the peak melting temperature recorded in the DSC
curve.

2.

Plot the Ionic conductivity, pmho/cm vs. Temperature at fixed frequencies
of 0.10 to 1.0 Hz.

3.

Measure the Ionic conductivity responses at < 30o C below the DSC
melting point temperature.

4.

From the measured responses plot an Arrhenius plot of DEA log ionic
conductivity vs. (K-1) x 1000 and perform a linear curve fit to determine
the equation of the line. The slope of the linear curve fit is Ea R-1and it
must be multiplied by 19.14to convert the slope value into Ea (J mol-1).
Note: Ea is the activation energy and R is the gas constant of 8.314 J K-
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1

mol-1 and one must include the conversion of natural log (ln) to log base

10, which is 2.303.
Ea (J mol-1) = (slope of the line) x 8.314 x 2.303
5.

The Ea (J mol-1) is inversely proportional to the concentration of the
amorphous phase in the pharmaceutical sample. Relatively, the lower the
Ea corresponds to a higher the ionic conductivity. The 1st DEA run
resulting in log conductivity vs. Temperature yielding % crystallinity
based on the DSC purity by Heat of Fusion (Jg-1). For an API the %
crystallinity is probably 100% for the 1st sampling by DEA. For the 2nd
and 3rd runs, samplings of the same API it will be less crystalline and
more amorphous, based on a lower Ea (J mol-1) value.

4. 3 Experimental
4.3.1 Drugs. The following drugs were evaluated in this study: Lidocaine (Tm,
68o C), Lidocaine HCl (Tm, 74-79o C), Sulfapyridine (Tm, 192o C), Indomethacin (Tm,
155o C), and Acetophenetidin (Tm, 135o C). All the drugs were obtained from SigmaAldrich® and meet the USP (United State Pharmacopeias) testing specifications.
Quetiapine fumarate (Seroquel®) (Tm, 173o C), and Procainamide HCl (Tm, 169o C) were
purchased from Haorui Pharma-chem Inc. Edison, NJ.
4.3.2 Experimental procedure. A TAI 2920 DSC (TA Instrument) was used to
profile the drug solid-solid transitions, melting, glass transition (Tg), and crystallization
properties of the drugs. All the samples were ramped at a rate of 10oC/min in purged
nitrogen gas flow at a rate of 60 mLmin-1 during heating and cooling cycles. The DSC
aluminum pan weighed 13-14 mgs. Samples in the range of 8-10 mg were weighed using
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the Mettler AT261 Delta Range® microbalance and loaded into an aluminum pan then
closed and crimped. Temperature range was typically from room temperature to 30o C
above the peak melting temperature (Tm) for the drugs under study. Heat flow (W g-1)
values versus temperature and time were generated using the (TA Thermal Advantage)
Universal Analysis 2000 software. The DSC instrument was calibrated using Indium as a
standard according to ASTM standard test protocol E967.
A TAI 2970 DEA (TA Instrument) was used to determine the electrical
conductivity and Tan delta curve for each drug studied. For each solid powdered drug, a
sample of approximately 20 mg was placed on a single surface gold ceramic
interdigitated sensor. The samples were ramped from room temperature to 30o C above
the melting temperature of the drug at heating rate of 10o C min-1. A purge gas of
nitrogen gas flowed at the rate of 60 mL min-1. The gold ceramic interdigitated sensor
was calibrated by the fixture supplied by TAI. The DEA instrument was further
calibrated according to ASTM E2038 Standard Test Method for Temperature Calibration
of Dielectric Analyzers. This standard method was employed for all the drugs studied at
5o C and 10o C min-1. Dielectric analysis was used to evaluate the electrical properties of
the drugs. The conductivity measurements were recorded at controlled interval
frequencies ranging from 0.10 to 10,000 Hz for all temperatures.
A Konica-Minolta DG SLR Camera with a 28-80 mm macro lens was used for
Macro- photomicrography to characterize the crystalline and amorphous materials on the
single surface interdigitated array gold electrodes, and samples on the DSC pans. An
eyepiece reticule was used to calibrate the Macro-photomicrography system.
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4.4 Results and discussions
We tested the applicability of the novel empirical method with several model
pharmaceutical APIs. When Lidocaine is heat cycled through the melt and then cooled
back to room temperature. The 1st DEA run of Lidocaine reveals the crystalline to
amorphous phase transition and change in the ionic dielectric conductivity from ≤ 10-2
(pS cm-1) for the crystalline phase and 105 (pS cm-1) for the amorphous phase. Figure 2
shows the DEA surface analysis profile for Lidocaine at 0.5Hz. Low frequency DEA is
confirmed as measurements at the electrode surface e.g. 0.5 Hz. The Lidocaine (Sigma
Aldrich®) sample is initially 99.99% crystalline with very low ionic conductivity for the
1st run and upon cooling and reheating a huge increase in ionic conductivity was
observed. The 2nd and 3rd runs commensurate with an increasing ionic conductivity value
of 103 pS cm-1 (79% amorphous) and 105 pS cm-1 (91% amorphous) see Figure 4.2. &
4.3. Figure 4.3 summarizes the % crystalline and % amorphous content in Lidocaine at
0.1, 0.5 and 1.0 Hz by the DEA “Empirical” method. Figure 4.4 summarizes the %
crystalline and % amorphous content in Quetiapine Fumarate (Seroquel®) at 0.1, 0.5 and
1.0 Hz by the DEA empirical method. Table 1 shows the list of drugs tested and
evaluated for crystalline and amorphous content by the proposed method (Table 1).
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Figure 4.2. DEA Surface Analysis of Lidocaine at 0.5Hz (1st, 2nd & 3rd Runs); DSC Tm 69.89o C

% amp = % Amorphous Content; % cry = % Crystalline
Content
Figure 4. 3. Determination of % Crystalline and % Amorphous content vs. Frequency/Hz for Lidocaine at 0.1, 0.5 &
1.0 Hz (Run1 to Run3) by the DEA Empirical method
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% amp = % Amorphous Content; % cry = % Crystalline Content
Figure 4.4. Determination of % Crystalline and % Amorphous content vs. Frequency/Hz for Quetiapine Fumarate at
0.1, 0.5 & 1.0Hz (Run 1 to Run 3) by the DEA Empirical method
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Table 1
Quantification of Crystalline and Amorphous Content in various Pharmaceutical APIs by
DEA Empirical method
Drug

Average content of 2nd and 3rd DEA Runs at 0.1,0.5 and 1.0 Hz
% Crystalline Content

% Amorphous Content

Sulfapyridine

9

81

Quetiapine Fumarate

10

90

Lidocaine

13

87

Procainamide HCl

19

81

Lidocaine HCl

24

76

Indomethacin

26

74

Acetophenetidin

78

22

Our second method to determine crystalline and amorphous content through the
measurement of DEA activation energies was tested with several model pharmaceutical
APIs. Results for Lidocaine and Acetophenetidin are discussed as follows. Analysis of
the Lidocaine by the proposed DEA empirical method yields a supportive interpretation
of the activation energy method, i.e. determination of the % crystalline and amorphous
content in a drug. Other APIs successfully tested by the activation energy method are
Sulfapyridine, Quetiapine Fumarate (Seroquel®), Procainamide HCl, Lidocaine HCl and
Indomethacin.
A plot of the DEA Log Ionic conductivity (pS cm-1) vs. Temperature (o C) for
crystalline Lidocaine is summarized in Figure 4.5. For the first run, we observed a slow
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rise in ionic conductivity till 60o C, (10-2 pS cm-1) followed by a very rapid increase (105
pS cm-1) from 60o C to 90o C. The DSC-DEA curve overlay maps out the melting
transition that occurs at 67o C. The second run cycling after the initial heat curve
produced a ionic conductivity response that was enhanced due to the formation of the
amorphous phase in Lidocaine, was observed from the temperature range of 40-70o C.
The slope of the first curve was steep and decreased significantly in the second and third
run. The slope change tracked the decreasing activation energy with each heat cycle. The
ionic conductivity increases proportionally with the enhanced amorphous content. A
curve fit of the log ionic conductivity vs. the reciprocal temperature in Kelvin produces a
linear curve with a correlation coefficient of R2= 0.999 and a varying activation energy,
for Lidocaine (Run 3) the Ea is 27 J mol-1 (see Figure 4.6.) for details.

Table 2

summarized the Lidocaine data in triplicate for the DEA Activation Energy method and
the determination of the % crystalline and amorphous content produced by a heat cycle at
three frequencies, 0.1, 0.5 and 1.0 Hz (all frequencies are associated with occurrences at
the sensor surface). The 2nd and 3rd runs produced an amorphous content of 93% at 0.1
Hz, 94% at 0.5 Hz and 1.0 Hz, (see Table 2).
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Figure 4.5. Lidocaine DEA and DSC curve overlay and comparing ionic conductivity in crystalline and amorphous
samples by activation energy method at 0.1 Hz to 1.0 Hz (Run1, Run 2 & Run 3); Tm= 69.89o C

Figure 4.6. Log conductivity (k) vs. 1/T (Kelvin) x 1000 for Lidocaine (Run 3, 0.1Hz); Ea = 27 J mol-1
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Table 2
Lidocaine DEA Activation Energy (J mol-1), % Crystalline and % Amorphous Content
for 1st, 2nd and 3rd Runs at 0.1, 0.5 and 1.0 Hz frequencies
Frequency/ Hz

Run

-1

Ea/J mol

% Amorphous
% Crystalline Content
Content

0.1

1

480

100

0

0.1

2

35

7

93

0.1

3

35

7

93

0.5

1

435

100

0

0.5

2

30

7

93

0.5

3

29

6

94

1

1

419

100

0

1

2

29

7

93

1

3

27

6

94

Evaluation of Acetophenetidin by the proposed DEA method for amorphouscrystalline content was an outlier in this protocol, since this drug recrystallizes
significantly while the other 6 drugs did not recrystallize to a noticeable extent. The
activation energy for Acetophenetidin described in (Figure 4.7. and 4.8.) yielded a high
value of 1240 J mol-1 at low ionic conductivities. It is our interpretation that this drug
continues to recrystallize and therefore the method to quantify the concentration ratio of
crystalline to amorphous varies. The 2nd and 3rd run produced varying values for the %
amorphous and % crystalline content with frequency. The content was frequency
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dependent for this drug but none of the other drugs evaluated. The 2nd and 3rd runs
produced an amorphous content of 25, 49 % for 0.1 Hz, 58, 70% for 0.5 Hz and 46, 69%
for 1.0 Hz, respectively.

Figure 4.7. Acetophenetidin DEA and DSC curve overlay and comparing Ionic conductivity in crystalline and
amorphous samples by activation energy method at 0.1 Hz to 1.0 Hz (Run1, Run 2 & Run 3); Tm= 135.80o C

Figure 4.8. Log conductivity (k) vs. 1/T (Kelvin)*1000 for Acetophenetidin (Run 1, 0.1Hz); Ea = 1244 J mol-1
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Quantification of the amorphous and crystalline content of the drugs studied by
the DEA Activation Energy Method is summarized in Table 3. A correlation was
established between the Empirical method & Activation Energy method resulting in the
correlation coefficient of R2= 0.925 for the overall average % amorphous content of all
the drugs studied (See Figure 4.9.).
Table 3
Quantification of Crystalline and Amorphous drug content of various pharmaceutical
APIs by the DEA Activation Energy Method
Drug

Average content of 2nd and 3rd DEA Runs at 0.1,0.5 and 1.0 Hz
% Crystalline Content

% Amorphous Content

Lidocaine

7

93

Sulfa pyridine

9

81

11

89

Procainamide HCl

19

81

Lidocaine HCl

22

78

Indomethacin

24

76

Acetophenetidin

47

53

Quetiapine
Fumarate

79

Figure 4.9. A correlation graph of Empirical Method versus Activation Energy Method (Ea) for the overall average %
amorphous content of all the drugs studied

Semi-qualitative evaluation of the amorphous and crystalline states by macrophotomicrography clearly denotes the two phases, (see Figure 4.10.) for Sulfapyridine at
2.4X magnification. See Figure 4.11. for amorphous melt of Lidocaine HCL after 3rd run.
All Pharmaceutical solids used in this study were characterized by this method. This
material characterization technique aids the development of the DEA methods for
identifying amorphous and crystalline character of the drug.

Figure 4.10. Macro photograph of DEA electrodes with sulfa pyridine in Crystalline Powder form (Right), and
amorphous form (left) at 2.4 X magnification

80

Figure 4.11. Macro photograph of DEA electrode with amorphous melt of Lidocaine HCl after 3rd Run

4.5 Conclusions
The most prominent conclusion is that we now have quantitative methods for
determining the crystalline and amorphous content of pharmaceutical solids by dielectric
analysis. We are basing this conclusion on the facts that the APIs distributed by
pharmaceutical companies are ≥ 99.99% pure crystalline solids. Once the crystalline state
is completely lost during melting the material becomes 100% amorphous.
Our studies reveal that 6 out of the 7 drugs evaluated showed this behavior of
complete amorphous formation. In the case of Acetophenetidin, it recrystallized rapidly
while the others remained predominantly amorphous. The crystalline and amorphous
content of the drugs as determined by the empirical method was frequency independent.
The frequencies studied relate to surface analysis at 0.1 - 1.0 Hz. The crystalline and
amorphous content of the drugs as determined by the activation energy method was
frequency dependent for one drug, i.e. Acetophenetidin. Therefore, Acetophenetidin was
an outlier for these methods. DEA for the first run of the APIs is 100% crystalline with
lower ionic conductivity and high activation energy, e.g., Acetophenetidin 1,200 -1,800
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Jmol-1. The second and third run of this drug showed repeatable variations with higher
ionic conductivity and lower activation energy observed from 470 to 930 J mol-1. The
other drugs investigated yielded a stable activation energy e.g. for Lidocaine crystalline
form it was 480 J mol-1 initially and for the amorphous form it was 27 J mol-1 at 1.0 Hz.
A comparison of overall average amorphous content by the Empirical method had
a linear relationship with the Activation Energy method with a correlation coefficient of
R2 = 0.925. The correlation coefficient for overall average crystalline content was R2=
0.94. After calibrating the DEA instrument, examining a 10 mg sample with a heating
and cooling profile plus interpretation time will lead to a definitive amorphous content in
one hour. Marco-photomicrography aids the DEA interpretation as an opaque solid
material as crystalline solid against the transparent amorphous material. These methods
determine the % amorphicity and % crystallinity and are significant contributions to the
analytical science of pharmaceuticals.
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CHAPTER V
PHYSICAL AND CHEMICAL CHARACTERIZATION OF HYDROCHLORIDE
SALTS OF DRUG SUBSTANCES BY DIELECTRIC AND CALORIMETRIC
ANALYSIS
5.1 Introduction
The critical factors for drug development of pharmaceutical formulations are the
solid-state properties of drug candidates. These solid-state properties are crucial in
selecting the appropriate salt form of a drug molecule as more than 50% of all the drugs
molecules used in the medicinal therapy are administered as organic salts [1-6]. For
large-scale production of the pharmaceutical formulations these salts of drug substances
must be suitable and technically feasible and its solid-state properties maintained batch
wise as well as over time. Changing salts in the middle of a development program may
require repeating most of the studies performed initially, i.e., biological, toxicological,
formulation, and physical and chemical stability.
However, selection of a nonoptimal salt may lead to increased developmental and
production costs, even product failure. Appropriate salt selection during the drug
development process can significantly reduce time to market and will avoid these
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problems and facilitate downstream development activities [2]. Salts are mainly used to
alter the physical, chemical, biological, and economical properties of a drug substance.
Salts with advantageous properties are usually patentable as new chemical entities. A
major reason for choosing a salt form is based on a needed change in the solubility of a
drug substance. Substances containing free acid and base groups have poor aqueous
solubility.
However, with the saltification (i.e., salt formation) of these acid and base groups
one can improve solubility, leading to greater bioavailability. The chloride, hydrogen
sulfate, phosphate, sodium, and potassium salts exhibit significantly higher solubility and
dissolution rates than the parent drug. In addition, salts usually exhibit a higher melting
point and improved chemical stability compared to the parent drug (free acid or base),
leading to greater stability and easier processing [4]. A choice of salts can also expand the
formulation options for a material. For example Lidocaine, a compound limited to
parenteral and topical formulations can be expanded to oral administration by changing it
to a salt form (e.g. Lidocaine hydrochloride) with acceptable physical properties [7]. The
different salts are different entities with altered behavior in the solid-sate and also in the
liquid state. These properties have to be studied taking into account thermodynamic,
surface, packing, mechanical and kinetic factors.
The most pertinent solid-state properties may affect the melting, heat capacity,
crystallinity

and/

or

amorphicity,

conductivity,

bioavailability,

pharmaceutical

processing, toxicity, therapeutic efficacy, quality, solid-state reactions, reactivity, and
stability of the drugs [8-14]. The International Conference on Harmonization (ICH)
requires proper investigations and analytical methods for drug substances and drug
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products following a decision tree (ICH) Q6A [15]. A number of analytical techniques
are commonly used for characterization of the salt of the drug substance: They are
thermal analysis, microcalorimetry and combined techniques, X-ray diffraction, solubility
and stability studies.
Salt formation involves proton transfer from the acid and base entity.
Theoretically, any substance or compound that exhibits acidic or basic characteristics can
form salts. The major consideration is the relative acidity and/ or basicity of the chemical
species involved. When using basic excipients in a formulation the relative acid/base
strength of the resulting salt and its tendency to disproportionate should be considered. A
common salt choice for basic drug substances approved by FDA is the hydrochloride
(most encountered anion is chloride), mainly because of its availability and highly polar
nature. However, due to the common ion effect, reports have shown that hydrochloride
salts do not always increase the solubility of poorly soluble basic drugs [16-19].
Thermoanalytical methods have been used in the pharmaceutical area for 35
years. They are employed for quality control, preformulation, drug-excipient interactions
and purity studies of raw materials and pharmaceutical products [20-24]. Thermal
analysis techniques mainly (DSC, DEA and TG) play an important role in the detection
of unexpected phase transitions and for the comparison of the suitability of the salt
candidate prepared from the salt selection [25]. The observance of the thermal phase
transitions by DSC is insufficient to fully characterize the behavior of a substance on
heating. The formation of hydrates and solvates can be investigated using
Thermogravimetry (TG). Other information, such as crystallinity and/ or amorphicity,
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conductivity, solid-state reactions, reactivity, physical and chemical stability of drug salts
can be obtained from dielectric analysis [26-29].
The pharmaceutical industry relies mainly on solid salts; primarily crystalline
forms for the delivery of the APIs because they are thermally stable, there are easy to
handle, and they are pure. In contrast, amorphous drug formulations are rarely found.
Salts in the crystalline form tend to melt and decompose, while salts in the amorphous
form have a glass transition (Tg) and no defined melt. However, crystalline solid forms
have low solubility and low bioavailability, compared with an amorphous form.
Amorphous forms have enhanced molecular mobility (poorer physical and chemical
stability) as compared to their crystalline counterparts, owing to their thermodynamic
(higher free energy) and kinetic properties (higher molecular represented by the
molecular relaxation time constant) [30]. The molecular mobility is usually expressed as
the polarization time, τ (Tau). The key factor responsible for their physical instability is
because of their greater molecular mobility. Several studies have recognized the role of
molecular mobility in time dependent recrystallization, chemical degradation, and
structural collapse of amorphous systems.
The observed molecular mobility is related to chemical reactivity of amorphous
pharmaceuticals [31-35]. These changes in the pharmaceuticals, may adversely lead to
altercations in the physicochemical properties and the bioavailability of the molecule
during storage. Therefore, an acceptable shelf life of amorphous compounds and their
formulations is of critical importance and this can be determined by reducing the
molecular mobility. However, a reduction in molecular motions does not necessarily
result in increased storage stability, because physical characteristics like: dielectric,
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mechanical and thermal properties may also vary with time and temperature on storage
[36]. For these reasons, a constant screening for new drug forms including salts is
ongoing and also because of financial interests caused by legal ramifications [37].
Several different techniques i.e., differential scanning Calorimetry (DSC), dielectric
analysis, isothermal microcalorimetry, mechanical analysis, and solid-state NMR
spectroscopy have been applied to study the relaxation or polarization phenomena in the
amorphous pharmaceutical systems.
The primary aim of this study is to investigate the thermal and electrical behavior
of pharmaceutical hydrochloride salts including the Lidocaine drug (non-salt) using DEA
and DSC techniques. This analysis provides a perspective on the use of the data from
these techniques for predicting the quality, stability and behavior of pharmaceutical salts.
This study is also aimed at providing a comprehensive characterization of ionic
conductivity and molecular mobility (related to tan delta in DEA) properties in
pharmaceutical salts i.e., crystalline and amorphous forms through the measurement of
the characteristic activation energies and polarization times.
5.2 Dielectric Analysis (DEA)
Riga et al. in 2005 published the first study of the physical-chemical properties of
drugs including drug salts and excipients by dielectric analysis [26]. DEA has come into
play in the pharmaceutical field because of its unique measurements, the electrical
properties of the drugs (APIs) or to determine their amorphous and crystalline content.
DEA measures the ability of dipoles and ions present in a material to align with an
application of a time dependent alternating electric field as a function of time,
temperature, and frequency [26 & 29]. The increase in molecular motion associated with
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the glass transition allows the dipoles or ions in an amorphous material to more freely
align with the electric field and dissipate energy. DEA measures two fundamental
characteristics of a material, in our study, of crystalline and amorphous drug salts. First,
the capacitive nature (permittivity; ε") of the drug salts allows these materials to store
electric charge. Second, the electrical conductivity (loss factor; ε!) characteristic
represents the ability of the drug salt to transfer electrical charge or energy to move ions.
DEA of pharmaceutical drugs, amino acids, organic chemicals, and carbohydrates
reveals a strong linear conductivity increase prior to the melt, peaking at the melt,
associated with the dielectric solid-state and viscoelastic properties of the material [26 &
38]. This DEA technique is a perfect complement to the other different techniques of
thermal analysis by identifying the phase transitions from the electrical properties of
materials as a function of time, temperature, and wide range of frequency (e.g. 0.1 Hz to
100,000 Hz) [39]. The wide frequency range allows measurement of subtle transitions as
well as multiple-mechanistic transitions that are sensitive to the frequency of
measurement. Matthews et al. characterized and distinguished the unique dipole
characteristics of chiral molecules, specifically 20 L-amino acids and 9 D-amino acids by
employing DEA as an analytical technique. This technique has the capability to explore
the rheology and molecular mobility of the amino acids 20 to 30 °C below the melting
temperature established by DSC [40].
Specific and novel protocols to quantify the crystalline and amorphous content of
various pharmaceutical drugs by dielectric and calorimetric analysis were developed by
Maheswaram et al. It was observed that the ionic conductivity of a crystalline drug is
typically less than 10-1 pS cm-1 at room temperature and a melted drug, an amorphous
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form, has a conductivity of greater than 105 pS cm-1. Further, the melted drug salts had an
ionic conductivity of >105 pS cm-1 [29]. The drug salts showed a 10-fold increase in ionic
conductivity, e.g., Lidocaine hydrochloride conductivity was 106 pS cm-1 and Lidocaine
(non-salt) 105 pS cm-1. The higher ionic conductivity is an important attribute of a drug
salt.
Examination of drug salts by DEA also discovered a strong linear electrical
conductivity prior to the pre-melt temperature through to the melt. Activation energies
(Ea, J mol-1) of each drug salt can be calculated from the slope of Arrhenius plots of the
log conductivity, Ea (k) versus reciprocal temperature in Kelvin [40]. This energy is
associated with the energy for charging ions in polar materials or relates to the formation
of charge transfer complexes prior to the melt in the solid state. Second activation energy,
Ea (τ, Tau) can be calculated via Arrhenius plots of log tan delta peak frequencies vs.
reciprocal temperature in Kelvin. This Ea (τ) is related to the activation energy for the
relative rate of change of the ordered charging process, molecular or charge mobility.
Therefore we can estimate the minimum energy attributed to charging of ions or creating
charge transfer complexes. Plus, the second Ea (τ) estimates the energy associated with
molecular mobility.
The polarization or the response time of the charged ion or ions can be measured
from a Debye plot, where the inverted peak value is corrected with a constant and
describes the time for the ions to be polarized for transport in the field. Therefore, DEA
can be a widely used thermal analytical method that measures polarization response of
various materials (e.g. drugs, chemicals, carbohydrates, proteins, electro rheological
fluids etc.) in an AC electric field at isothermal temperatures or by scanning temperature
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techniques [38-44]. The response times were calculated from a Debye plot of tan delta
(ε!/ ε") vs. log frequency. The response time is directly related to the polarization time,
which is inversely related to the critical peak frequency in the Debye plot [38]. The
polarization time is calculated by using the following equation:
Τ (Tau) = 1/2πfc x 1000 (MS) [see references 38, 45]
τ (Tau) = Polarization time (millisecond)
fc = Tan delta critical peak frequency (Hz)
These analyses demonstrate efforts to correlate the polarization (relaxation)
properties to the molecular structure and behavior of the material [46].
5.3 Differential Scanning Calorimetry (DSC)
DSC is frequently used to measure the physical properties of Active
Pharmaceutical Ingredients (APIs), and Excipients. This includes melting and
vaporization temperatures, phase transitions, glass transition, stability, quality and purity
studies of raw materials and pharmaceutical products. The quality of these
pharmaceutical materials is based on the melting temperature and peak melting
temperature, a range of 2 to 3 °C, i.e. melting peak temperature (Tmp) minus the melting
temperature (Tm). The heat of fusion of a drug or drug salt is a criterion for drug
crystalline/amorphous content and its purity. The heat of fusion is usually much greater
for the salt that melts and decomposes vs. the one that only melts. The DSC curve for the
former is typically broader at its half maximum, e.g. during decomposition the value is
17-20 °C and for a pure stable salt the half maximum is 3-5 °C. The DSC decomposition
temperature of the drug salt as an exothermic or endothermic process is a key indicator
that the drug is unstable. The apparent heat of fusion for a pure drug is <300 J/g while the
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drug salt melting and followed by decomposition, probably endothermically, is 400-500
J/g. The DSC curve profile is also spiked detected as a second endothermic peak along
with the melting the first endotherm.
Careful analysis of the DSC amorphous phase can reveal molecular mobility of
the pharmaceutical that can be related to its performance. Amorphous materials have
varying properties from their crystalline counterparts. Differences in the amorphous
forms can be related to their kinetic solubility, storage stability as well as their
mechanical characteristics [47]. These physical amorphous forms lead to unique physical
chemical attributes and functionalities.
5. 4 Experimental
5.4.1 Materials.

The following drug salts were studied by DSC & DEA.

Procainamide hydrochloride (Tm, 169 °C), Lidocaine (Tm, 68 °C) and Lidocaine
hydrochloride (Tm, 74–79 °C) were obtained from Sigma-Aldrich (St. Louis, Mo.).
Fluoxetine hydrochloride (Tm, 156-158 °C) was obtained from Eli Lilly. Hydralazine
hydrochloride (Tm, 273 °C) was obtained from Alfa Aesar; Quinapril hydrochloride was
obtained from Toronto Research Chemicals Inc. (Tm, 120-130 °C).
5.4.2 Uses. Fluoxetine hydrochloride (Figure 5.1.) is an antidepressant of the
selective serotonin reuptake inhibitor class. The multiple aromatic rings that are in
conjugation with the highly electronegative fluorine atoms promote its structural stability.
Hydralazine hydrochloride (Figure 5.2.) is a smooth muscle relaxant and is an
antihypertensive. Its potential stability is based on the ring structures but the terminal
amine is vulnerable and is less stable. Quinapril hydrochloride [48] (Figure 5.3.) is an
angiotensin-converting enzyme inhibitor (ACE inhibitor) used in the treatment of
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hypertension and congestive heart failure. Procainamide hydrochloride (Figure 5.4.) is an
anti-arrhythmic agent used for the treatment of cardiac arrhythmias. Lidocaine
hydrochloride (Figure 5.5.) is a local analgesic used quite frequently in dentistry and as
antiarrhythmic drug. Its stability can be based on the ring conjugation with the carbonyl.
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Figure 5.1. Skeletal structure of Fluoxetine hydrochloride
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Figure 5.3. Skeletal structure of Quinapril hydrochloride
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Figure 5.4. Skeletal structure of Procainamide hydrochloride
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Figure 5.5. Skeletal structure of Lidocaine hydrochloride

5.5 Instrumentation
5.5.1 Differential scanning calorimetry (DSC). A TAI 2920 DSC was used to
characterize melting, solid-liquid phase transitions, glass transition temperature (Tg) of
pharmaceutical hydrochloride salts. Approximately 8-10 mg of sample was mass out and
placed in sealed aluminum crimped pan (SFI pans) with a pinhole. An empty SFI
aluminum pan was used as a reference. A heating rate of 10 °C min-1 was applied to all
samples. A purge gas of nitrogen was flowed at a rate of 60 mL min-1 during heating and
cooling cycles. The temperature range was typically from room temperature to 25 to 30
°C above the melting temperature (Tm) for the salts under study; the glass transition was
also evaluated and then cooled to room temperature. DSC equipment was preliminarily
calibrated with standard reference of indium (Tm, 156.6 °C). The purity determination
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was accomplished with an E698 protocol an ASTM Method. Heat flow (W g-1) values vs.
time and temperature were generated using Universal Analysis 2000 (TA Thermal
Advantage) software.
5.5.2 Dielectric analysis (DEA). A TAI 2970 DEA was used to determine the
electrical ionic conductivity and Tan delta (ε!/ε") for each drug salt studied.
Approximately 20 mg of sample was placed on a single surface gold ceramic
interdigitated electrode (entire electrode was covered). The sample were linearly heated
at a rate of 10 °C min-1 in a purged inert nitrogen gas flow at rate of 60 mL min-1 from
room temperature to 25-30 °C above the melting temperature of the salts studied. The
samples were heated, using the above heating protocol, and air cooled for sequential runs.
The DEA sensors were calibrated by the TA instrument software, which was initially
calibrated by a 9-step fixture supplied by TAI. The ionic conductivity (pS cm-1) and tan
delta measurements were recorded at a controlled interval frequencies ranging from 0.10
to 10,000 Hz for all the temperatures. These DEA curves were generated using the
Universal Analysis 2000 software (TA Thermal Advantage software).
5.6 Results and Discussion
5.6.1 Dielectric analysis: Ionic Conductivity (pS cm-1). DEA profiles of the
drug salts studied show that the initial ionic conductivity for a crystalline drug is 10-2 pS
cm-1. The ionic conductivity of the amorphous form (liquid) of a non-salt drug (e.g.
Lidocaine) is 105 pS cm-1. The drug salt in the amorphous form will have an ionic
conductivity of 106-108 pS cm-1 in the melt. Therefore, the liquid drug salts can be
modified by electrochemical synthesis in the melt state based on their enhanced ionic
conductivity.
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The DEA profile of Fluoxetine.HCl shows the changes in electrical behavior
associated with solid-solid and solid-liquid transitions. The DEA curve shows a sharp
linear increase in ionic conductivity leading up to the melt (DSC 157-161oC) in the first
run and an increase in ionic conductivity with temperature in the second and third runs.
The ionic conductivity of the Fluoxetine HCl for the crystalline solid at 0.5 Hz (DEA 1st
run) was 2.18 x 10-3 pS cm-1 at 54.34 o C and at 0.5 Hz it was 55.15 pS cm-1 at 140.60o C.
In the melt region for DEA run 1 at 0.5 Hz it was 1.12 x 107 pS cm-1 at 164.99o C
and at 10,000 Hz it was 5.30 x 107 pS cm-1. For the DEA 2nd run the ionic conductivity at
10,000 Hz was 1.06 x 108 in the melt (164.99o C) and at 0.5 Hz, 139.94o C it was 4.2 x
105. For the 3rd run at 10,000 Hz, 164.81o C the ionic conductivity was 1.07 x108 pS cm-1
and at 0.5 Hz, 139.79o C it was 5.13 x 106 pS cm-1 (See Figure 5.6.). The DSC curve for
Fluoxetine HCl reveals a sharp Tm at 157.45o C and a heat of fusion of 130 J.g-1 (See
Figure 5.7.). On the cooling cycle it doesn’t recrystallize and therefore it indicates the
formation of an amorphous material.

Figure 5.6. Log ionic conductivity versus Temperature profile, frequency range of 0.50 Hz – 10,000 Hz, of
Fluoxetine.HCl; Overlay of DEA 1st, 2nd and 3rd runs
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Figure 5.7. Fluoxetine.HCl DSC curve showing Tm = 157.45o C, Heat of fusion (130 J g-1) for the first endothermic
peak

The DSC and DEA profiles of Procainamide.HCl are compiled in Figure 5.8. The
DSC profile yielded the Tm = 166.63 oC and Tmp (peak melting temperature) = 169.61 o
C plus the heat of fusion = 104.50 J g-1. The DEA ionic conductivity results are as
follows: 1st run, 59.80 oC, 0.50 Hz, 4.69 x 10-2 pS cm-1; 152.18 oC, 0.50 Hz, 1.55 x 103 pS
cm-1; 169.56 oC, 0.50 Hz, 6.63 x 105 pS cm-1. For the 2nd run, at 59.77 oC, 0.50 Hz, 6.44 x
103 pS cm-1; 152.18o C, 0.50 Hz, 3.36 x 106 pS cm-1; 169.53o C, 0.50 Hz, 1.01 x 108 pS
cm-1. Consequently, from the crystalline solid (run 1) to the amorphous liquid (run 2) at
0.50Hz and 152 oC the ionic conductivity increased by 2200 times and at 169 oC it
increased by 150 times. There is statistical significant difference in ionic conductivity
from crystalline to amorphous form of the drug salt. Therefore, the first runs of
Fluoxetine.HCl and Procainamide.HCl are more stable and are of higher quality than the
higher conducting amorphous second and third runs.
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Figure 5.8. Overlay of DSC and DEA (1st, 2nd and 3rd runs) profile of Procainamide HCl showing DEA log ionic
conductivity versus temperature profile, frequency range of 0.50 Hz to 10,000 Hz and DSC profile Tm = 166.6; Tmp =
169.6o C, Heat of fusion = 104.5 Jg-1

The higher ionic conductivity is an important attribute of a drug salt. The DEA
ionic conductivity of Lidocaine (non-salt) is 105 pS cm-1 and Lidocaine. HCl is 106 pS
cm-1 for the amorphous form of the drug salt (2nd run). Clearly the ionic salt (HCl) is
contributing to the measured higher conductivity, a ten-fold increase. A quality drug salt
attribute is that the 1st DEA run ionic conductivity is low at room temperature (10-2 pS
cm-1). As the salt is heated and approaching the melt, in the pre-melt temperature range
the conductivity increases from ca.10-1 to 106 pS cm-1. Next, in the melt of the drug salt
the conductivity is >106 to 108 pS cm-1. Further, the DSC profile yields a curve where the
endothermic melt is a smooth narrow peak with half maxima of 3-5 oC. A drug salt that
melts and decomposes has a half maxima of >15 oC., e.g. Hydralazine.HCl. Its apparent
heat of transition, fusion and endothermic decomposition was 300 - 400 J g-1. This
supports the DEA interpretation of first run (crystalline solid; 104 pS cm-1) ionic
conductivity decreased on the second run (103 pS cm-1) atypically.
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5.6.2 Activation Energies (J m-1). It has been observed that some chemicals,
amino acids and carbohydrates form charge transfer complexes prior to the melt in the
solid state [29, 40]. A study of the electrical behavior of the drug salts, as determined for
the amino acids and sugars, yielded repeatable activation energy values which can be
correlated with real world solid-state properties, e.g. stability and/or quality. Activation
energies (Ea, J mol-1) of each drug salt either as related to the conductivity (k) or to the tan
delta (e”/e’) peak frequencies (τ) can be calculated from the slope of Arrhenius plots of
the log conductivity, Ea (k) or Ea (τ) versus 1/ temperature (K) x 1000. Therefore we can
estimate the minimum energy attributed to charging of ions or creating charge transfer
complexes and the energy associated with molecular or charge mobility.
The Activation energies Ea (k) (J m-1) for the drug salts were evaluated at 0.50 Hz
and at a temperature range of 20 oC to 30 oC below the DSC peak melting temperature
employing an Arrhenius plot (See Table 1). The Ea (k) for Fluoxetine HCl (See Figure
5.9.), Procainamide HCl (See Figure 5.10.), and Quinapril HCl (See Figure 5.11.) were
calculated from the DEA plots of Ionic conductivity (pS cm-1) vs. temperature. DEA 1st
run (Crystalline Solid); DEA 2nd run (Amorphous), and 3rd run (Amorphous) Ea (k)
values for all the drug salts studied are summarized in Table 1.
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Table 1
Activation Energies Ea (k) of Drug Salts
Activation Energies: Ea (k) J m-1
DEA 1st Run

DEA 2nd Run

DEA 3rd Run

Crystalline

Amorphous

Amorphous

Procainamide.HCl

501

81

83

Fluoxetine.HCl

956

227

35

Lidocaine.HCl

340

33

31

Quinapril. HCl

380

176

134

Drug Salts

Figure 5.9. Overlay of DEA (1st, 2nd and 3rd runs) log ionic conductivity versus temperature profile of Fluoxetine
HCl at 0.50 Hz
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Figure 5.10. Overlay of DSC and DEA (1st, 2nd and 3rd runs) profile of Procainamide HCl showing DEA log ionic
conductivity versus temperature profile at 0.50 Hz and DSC profile Tm = 166.6; Tmp = 169.6o C, Heat of fusion =
104.50 J g-1

Figure 5.11. Overlay of DEA (1st, 2nd and 3rd runs) log ionic conductivity versus temperature profile of Quinapril
HCl at 0.50 Hz

The Ea (k) for the 4 crystalline drug salts studied (DEA 1st run) was 340-956 Jm-1.
The Ea (k) for the 2nd and 3rd runs of Procainamide.HCl (501 J m-1) and Lidocaine.HCl
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(340 J m-1) decreased from a higher value to a constant lower value of 82 and 32 J m-1,
respectively. Fluoxetine.HCl and Quinapril.HCl decreased by 85% and 24% of the 1st
run Ea (k) value, respectively. A curve fit of the log conductivity vs. 1/T (K) x 1000
produced a linear curve with a correlation coefficient of R2 = 0.996 or greater for all the
drug salts (see Figure 5.12. for Fluoxetine.HCl Arrhenius plots). The Ea (k) is used to
rank crystallinity/amorphicity in pharmaceutical solids [29], that is, a high Ea (k) value is
crystalline material and low Ea (k) value is amorphous material. An Ea (k) value of <140
J m-1 suggests that the material is amorphous.

Figure 5.12. Arrhenius plots of Fluoxetine.HCl (1st, 2nd, 3rd runs; 0.5Hz); Ea = 956, 227, 35 J m-1 respectively

5.6.3 Tan delta. The Activation energies Ea (τ) for the drug salts were evaluated
as a function of frequency and temperature. An Arrhenius plot was used to determine the
Ea (τ) for each drug salt i.e. crystalline or amorphous material. The log tan delta peak
frequencies (Hz) vs. reciprocal temperature in Kelvin x 1000 for the drug salts studied is
summarized in Table 2. Tan delta curves for all the drug salts revealed a weak spectrum
in the first run of the crystalline solid (Figure 5.13.). The second and the third runs
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revealed strong spectra (See Figure 5.14. and 5.15. respectively). The resulting Ea (τ)
only yields values after the 2nd and 3rd DEA scanning runs, as the material is amorphous.
The Ea (τ) from run 2 to run 3 was constant for Procainamide.HCL at 84 J m-1 (See
Figure 5.16.), Fluoxetine.HCl at 78 J m-1 and Quinapril.HCl at 25 J m-1. The constant Ea
(τ) values in the amorphous phase indicate the presence of a stable material. For
Lidocaine.HCl, the Ea (τ) varied from the 2nd run (148 J m-1) to the 3rd run ending in (20 J
m-1). This can be interpreted that there is some variability in this salt possibly related to
the hydroscopic nature of this compound. The water aggregating on the salt can cause the
variation in its solid – liquid state properties. This analysis scheme can be developed to
predict storage stability or shelf life with a detailed experimental analysis based on the Ea
(τ).
Table 2
Activation Energies Ea (τ) of Drug Salts
Activation Energies : Ea (τ) J m-1
DEA 1st Run

DEA 2nd Run

DEA 3rd Run

Crystalline

Amorphous

Amorphous

Procainamide.HCl

Not Observed

84

85

Fluoxetine.HCl

Not Observed

78

79

Lidocaine.HCl

Not Observed

148

20

Quinapril.HCl

Not Observed

25

25

Drug Salts
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Figure 5.13. Tan Delta versus log frequency profile of Fluoxetine.HCl (DEA 1st run)

Figure 5.14. Tan Delta versus log frequency profile of Fluoxetine.HCl (DEA 2nd run)
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Figure 5.15. Tan Delta versus log frequency profile of Fluoxetine.HCl (DEA 3rd run)

Figure 5.16. Overlay of Tan Delta versus log frequency profile of Procainamide.HCl (DEA 1st and 3rd runs)

5.6.4 Polarization times (ms). The polarization times for these drug salts were
calculated from a Debye plot of tan delta (ε!/ ε") vs. log frequency. These analyses
demonstrate efforts to correlate the polarization (relaxation) properties to the molecular
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structure and physical as well as electrical behavior. The polarization or response time to
the AC electrical field produces a peak value where the loss factor is equal to the
permittivity (ε!= ε") and the molecular mobility is enhanced. This enhanced molecular
mobility behavior of the amorphous materials is thought to be the cause of their
significant tendency towards crystallization, structural collapse, and chemical
degradation. Studying the polarization times and the accompanying activation energy Ea
(τ) gives us the opportunity to determine the effect of environment on the molecular
mobility of the drug salts. We can also predict the storage stability or desirable shelf life
of crystalline/amorphous pharmaceutical systems.
The polarization time for Fluoxetine.HCl DEA 1st run (crystalline solid) was 690
milliseconds. For Lidocaine.HCl and Procainamide.HCl the τ was 530 milliseconds
indicating longer polarization times reflecting a stable material. The 2nd and 3rd DEA runs
of the amorphous form of the drug salts exhibited a distribution of polarization times due
to the dynamically heterogeneous nature of the amorphous state. However, a crystalline
Quinapril.HCl after the first DEA run produced a τ of 0.320 milliseconds, shorter times
for a crystalline drug salt is indicative of enhanced molecular mobility behavior. This
change suggests a structural collapse or chemical degradation as the crystalline material
becomes amorphous.
5.7 Conclusions
In the development of the solid pharmaceutical forms, quality control, stability
and behavior of the materials are important parameters to ensure the final product quality.
This study aids in the selection and evaluating the drug salt candidates by DEA and DSC
techniques. Salts with advantageous properties are typically patentable as new chemical
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entities. The relative amount crystalline/amorphous content in pharmaceutical solids can
be clearly identified by DEA activation energy, Ea (k) [29]. The higher conductivity of
the salt promotes better solubility and bioavailability characteristics. Evaluation of drugs
by DEA yields to a more conducting amorphous phase with the HCl salt e.g.
Lidocaine.HCl (106 pS cm-1) and Lidocaine (105 pS cm-1). The DSC melting profile of
the salt form of Lidocaine (i.e. Lidocaine.HCl) had a higher melting temperature or a
more stable phase. The first DEA run of the drug salts are more stable and of higher
quality than the higher conducting amorphous 2nd and 3rd runs. A combination of DEA
and DSC profiles can identify a vulnerable drug salt through decomposition (e.g.
Hydralazine.HCl).
The identification of the pre-melt and melt ionic conductivities and activation
energies for the drug salts appears to be a pathway for establishing the experimental
conditions that can be used to modify the quality, stability and performance of the final
drug product. We can predict the minimum activation energy Ea (k) attributed to
charging ions or creating charge transfer complexes and activation energy Ea (τ)
associated with charge mobility. The DEA properties described here can be further
developed to estimate the storage stability or shelf life of the drug salts by Ea (τ) and
polarization times. Stable drug salts by DEA evaluation renders an Ea (τ) that is constant
in the 2nd to the 3rd DEA runs. The approaching stability of the amorphous phase relates
that the Ea (τ) remains constant, as observed for Lidocaine HCl.
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CHAPTER VI
DIELECTRIC PROPERTIES OF PHARMACEUTICAL SOLIDS REVEAL
UNIQUE AMORPHOUS CHARACTERISTICS: VALIDATED BY THERMAL,
MICROSCOPIC AND X-RAY METHODS
6.1 Introduction
Diffraction techniques are the most defined methods for detecting and
quantifying the crystalline and amorphous content in any pharmaceutical system. For
example, Powder X-ray Diffraction Analysis (PXRD) of APIs and excipients gives a
good observation of the crystalline phase. The diffraction planes of the given sample
delineate the interplanar distances that identify the crystalline character. The area under
the diffraction peaks, either a key intense peak or series of peaks, can be related to the %
crystallinity. The amorphous content in this analysis is then measured by difference from
100% crystalline. Alternately, the amorphous phase is only seen as broad diffuse XRD
bands. The area under the amorphous bands has been correlated to the amorphicity, but
with a great deal of specific requirements per XRD pattern. Although, these methods only
“observe” the molecular order, and the disorder in the system is predicted by the absence
of the order [1].

Complications and errors in interpretation arise due to complex
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scattering patterns of the sample, weak diffraction peaks, preferred crystal orientation,
and optimized particle size so as not to contribute to line intensity broadening, and finally
instrumental errors. The main disadvantage in using this approach is that it cannot
differentiate surface/ bulk amorphicity.
Additional analytical techniques used to characterize amorphous pharmaceutical
solids with thermal energy as the basic principle are DSC, IMC, and SC. DSC is the most
relevant and significant method that is used to characterize the melting behavior, purity,
glass transitions, crystallization, polymorphism, solid-solid transitions and chemical
reactions of the drug including the detection of the amorphous content [2, 3]. DSC is
performed by heating the sample through its melting point with linear heating rate of 2.0
to 10 oC min-1. As Tg is the characteristic property of amorphous material, the DSC scan
of an amorphous or blend of crystalline/ amorphous material shows a glass transition,
with crystallization exothermic peak, and melting endothermic peak [1, 2, 4]. Amorphous
content is quantified in a sample by preparing a calibration curve using 100% amorphous
and crystalline standards and their blends, and with their respective heats of fusion (∆Hf)
and crystallization [2].
Using, XC (%) = (∆H/∆Ho)*100

[1, 2, 4]

Where, ∆His the Heat of fusion of the sample and ∆Ho is that of the 100% crystalline
standard. Also, amorphous content can be calculated without the calibration curve using
the equation:
Amorphous content = ∆Hf amorphous /∆Hf crystalline
Where, ∆Hf amorphous is heat of fusion of amorphous portion and ∆Hf crystalline is
the heat of fusion for the pure crystalline material.
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Although proven, DSC technique shows several drawbacks: that it cannot
differentiate surface vs. bulk amorphicity; thermal changes in the sample during the scan
or given time after the scan; crystallinity is measured during the melting process. The key
parameter for identifying the amorphous phase is the glass transition temperature.
However, the amorphous content is only qualitatively related to the Tg and not
quantitatively proportional to it. In order to obtain reliable results several variables like
sample size, sample pan used (open or closed), and the thermal contact resistance
between the sample pan and the DSC cell has to be considered.
It is well known that DSC melt properties are correlated to the structure of the
drug, which can be validated by a variety of structural tools like PXRD [2, 5] and
Scanning Electron Microscopy (SEM) [2]. Morphological and thermodynamic transitions
in drugs as well as their amorphous and crystalline content in the solid state have been
initiated by thermal analytical techniques, which include Dielectric Analysis [3, 5].
The primary aim of this study is to achieve the amorphization of the APIs
Clopidogrel hydrogen sulfate [6] and Quinapril.HCl [7] by solvent evaporation method.
A further aim is to characterize the crystalline and amorphous content in these APIs by
the DEA activation energy method. Finally, the dielectric science developed to
understand the crystalline and amorphous components in pharmaceuticals would be
validated by Calorimetry, X-ray diffraction and scanning electron microscopy.
6.2 Materials and Experimental Procedure
6.2.1 Materials. The following drugs were evaluated in this study: Lidocaine.HCl
(Tm, 74°-79°C), Sulfapyridine (Tm, 192°C), Indomethacin (Tm, 155°C), Quetiapine
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fumarate (Seroquel®) (Tm, 173°C), Procainamide.HCL (Tm, 169°C), Clopidogrel
hydrogen sulfate (Tm, 177.4 °C), Quinapril.HCl (Tm, 120-130 °C).
6.2.2 Preparation of amorphous form of a drug
6.2.2.1Clopidogrel Hydrogen sulfate (CHS). Amorphous samples were made
using ethanol. 100 mg of CHS was dissolved in sufficient amount of ethanol with
magnetic stirrer for 5 min at room temperature [6]. The solvent was evaporated by two
methods: with blown room temperature air or by vacuum. After drying, samples were
pulverized in a porcelain mortar with a pestle. DEA, DSC, PXRD and SEM techniques
were used to characterize the amorphous and crystalline forms of Clopidogrel hydrogen
sulfate.
6.2.2.2 Quinapril.HCl (Q.HCl). Q.HCl was dissolved in a minimum amount of
dichloromethane required to form a solution [7]. The solvent was removed initially using
a rotary evaporator under vacuum at room 30o C, and the residue was dried under vacuum
for 24 hrs. DEA, DSC, PXRD and SEM techniques were used to characterize the
amorphous and crystalline forms of Q.HCl.
6.2.3 Experimental procedure.
6.2.3.1 Differential scanning calorimetry. DSC studies were performed with a
TAI 2920 DSC instrument with samples of approximately 5-10 mg weighed into nonhermetically sealed pans. The samples were heated from room temperature to 20 oC
above the peak melting temperature at a heating rate of 10 oC/min. The instrument was
calibrated with use of indium.
6.2.3.2 Dielectric analysis. A TAI 2970 DEA (TA Instrument) was used to
determine the electrical conductivity for each drug studied. Sample of approximately 20
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mg was placed on a single surface gold ceramic interdigitated sensor. The samples were
ramped at a rate of 10 oC min-1 from room temperature to 20 oC above the melting
temperature of the drug. The conductivity measurements were recorded at controlled
interval frequencies ranging from 0.10 to 10,000 Hz for all temperatures.
6.2.3.3 X-ray powder diffraction (PXRD). XRD patterns were obtained using an
X’Pert PRO MPD system (X-ray Diffractometer Phillips). Where the tube anode was Cu
with Kα1= 1.5408 Å. The pattern was collected at a tube voltage of 45kV and a tube
current of 35 mA in step can mode. Angle range: 10o to 80o 2Θ. The data were evaluated
with origin software or JADE software. The powder diffraction files come from the
International Center for Diffraction Data (ICDD).
6.2.3.4 Scanning electron microscopy. The surface morphology of various
amorphous drug samples was investigated using an Amray 1830 scanning electron
microscope. The dry powder was mounted onto metal stubs by applying silver paint onto
the metal stubs. The drug sample was sprinkled on the silver paint and then it is dried.
Then the samples are vacuum-coated with a platinum film using a gold sputter coater
unit.
6.3 Results and Discussion
We tested the applicability of the novel activation energy method for quantifying
crystalline and amorphous content with several other pharmaceutical solids including the
amorphous forms of the API prepared by solvent evaporation methods e.g., Clopidogrel
hydrogen sulfate and Quinapril.HCl. The DEA results obtained from the activation
energy method for all the drugs studied were validated with other established methods,
e.g., DSC, PXRD and SEM analysis.
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6.3.1 DEA study. The comparison of four runs of Clopidogrel hydrogen sulfate
by DEA and DSC are overlayed in Figure 6.1. The ionic conductivity in crystalline and
amorphous samples as a function of temperature were used to calculate the activation
energy from 0.1-10,000 Hz (first and second runs) [8, 9]; Clopidogrel HS pure
amorphous sample DEA run overlays the DEA amorphous run 2; DSC Tm = 176.11oC,
Tmp = 179.42 oC, Heat of fusion = 81.33 J/g. Therefore, the DEA 2nd run was the same
as the 1st run prepared out of the DEA i.e., the sample prepared with ethanol by solvent
evaporation method, was amorphous. To confirm that the prepared sample was
amorphous, a DSC analysis was performed (See Figure 6.2). The characteristic melting
point disappeared completely from the DSC curve; a Tg [10] was observed. The resulting
Tg was at 89 oC and the ΔCp at Tg was 0.256 J/g/C. The result confirms the presence of
the amorphous form by DEA and DSC.
Figure 6.3. shows the DEA surface analysis profile for Clopidogrel hydrogen sulfate at
0.1 Hz.

Figure 6.1. DEA and DSC curve overlay of Clopidogrel hydrogen sulfate. DEA 1st run Crystalline (Green) and 2nd
run Amorphous (Blue); DEA 1st run pure amorphous form (Prepared (Brown)
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Figure 6.2. Glass transition temperature of Clopidogrel hydrogen sulfate measured by DSC; Tg = 89.32o C

Figure 6.3. Clopidogrel hydrogen sulfate DEA curve overlay of crystalline and amorphous sample by activation energy
method surface analysis at 0.1 Hz (first and second runs)
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Table 1 identifies the activation energies for Clopidogrel hydrogen sulfate (Ea in J/mol)
with the higher value for the crystalline form (DEA 1st run) and a significantly lower
value for the amorphous form (DEA 2nd run). For the 2nd run at 0.1, 0.5, and 1.0 Hz the
amorphous sample content was 76-78% (See Table 2).
Table 1
Clopidogrel hydrogen sulfate DEA activation energy (J/mol), % crystalline, and %
amorphous content for first and second runs at 0.1, 0.5, and 1 Hz frequencies
Clopidogrel
Frequency/

DEA

Ea/

% Crystalline

% Amorphous

Hz

Run

Jmol-1

content

content

Crystalline

0.1

1

622

100

0

Amorphous

0.1

2

138

22

78

Crystalline

0.5

1

576

100

0

Amorphous

0.5

2

136

24

76

Crystalline

1

1

576

100

0

Amorphous

1

2

138

24

76

hydrogen
sulfate

Table 2 summarizes Clopidogrel hydrogen sulfate DEA activation energies for the pure
crystalline form and the pure amorphous form, for Run1 at 0.1, 0.5 and 1.0 Hz.
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Table 2
Clopidogrel hydrogen sulfate DEA activation energy (J/ mol), % Crystalline, and %
amorphous content for first run crystalline sample and first run pure amorphous sample
Clopidogrel

Freq/
Run

-1

% Crystalline

% Amorphous

Content

Content

Ea/ J mol

hydrogen sulfate

Hz

Crystalline

0.1

1

622

100

0

0.1

1

138

22

78

0.5

1

576

100

0

0.5

1

130

23

77

1

1

576

100

0

1

1

127

22

78

Amorphous
(Pure)
Crystalline
Amorphous
(Pure)
Crystalline
Amorphous
(pure)

Quantification of crystalline and amorphous drug content of Clopidogrel
hydrogen sulfate by DEA activation energy method is summarized in Table 3. The
activation energies for the DEA amorphous form of the drug (2nd run) correlate with
activation energies for the pure amorphous form prepared with ethanol (1st run). The
average content of the DEA 1st run for the pure amorphous form prepared with ethanol
was 22% crystalline and 78% amorphous (0.1- 1.0 Hz). For the 2nd run of DEA
amorphous form the average content was 23% crystalline and 77% amorphous (0.11.0Hz).

125

Table 3
Quantification of crystalline and amorphous drug content of Clopidogrel hydrogen sulfate
by DEA activation energy method
Average content of DEA first run (pure Amorphous Form)
at 0.1, 0.5, and 1.0 Hz

Drug

% Crystalline content

% Amorphous content

22

78

Clopidogrel
hydrogen sulfate

The summary table 4 describes the average value of the content, both % crystalline and
amorphous, for the drugs studied by DEA activation energy method, at various
frequencies for the 2nd and 3rd DEA runs.
Table 4
Quantification of crystalline and amorphous drug content of various pharmaceutical APIs
by the DEA activation energy method
Average content of second and third DEA runs
Drugs
at 0.1, 0.5, and 1.0 Hz
% Crystalline content

% Amorphous content

Clopidogrel hydrogen sulfate

23

77

Quinapril HCl

35

65

Quetiapine Fumarate

11

89

Lidocaine.HCl

22

78

Sulfapyridine

19

81
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6.3.2 DSC study. A well-established tool for pharmaceutical analysis is DSC,
which can examine the degree of fusion and crystallization of an API. The heat of fusion
(J/g) associated with the first DSC examination of the crystalline API (run 1) is recorded.
The thermal analysis curve represents a physical chemical property of the sample drug,
i.e., melting. Cooling of the API sample after melting through the crystallization yields
the temperature and heat of crystallization (J/g). This cooling DSC data is a measure of
the amount of sample recrystallized.
The ratio of the heat of crystallization divided by the heat of fusion times 100 is
the % crystalline and the difference is the % amorphous content. For example,
Sulfapyridine melts at a 192 oC (run 1) and crystallized at 123 oC (run 2) in the DSC
Cooling cycle. The measured heat of fusion was 174 J/g and heat of crystallization was
57 J/g, see Figure 6.4. Therefore the recrystallized sample contained 33% crystalline and
67% amorphous material. The % amorphous by DEA activation method is 81% and by
this DSC heat-cool method is 67% amorphous. The other drugs analyzed by the DSC
heating and cooling cycles are listed in the Table 5.
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Figure 6.4. DSC curve of Sulfapyridine showing Heat-Cool cycle; Tm = 191oC, Tmp =194.39o C, Heat of Fusion =
174 J/g; Heat of Crystallization = 57 J/g, Tmc=119oC, Tmpc = 123o C

6.3.2.1 Confirmation of amorphous form by DSC. Prepared amorphous sample
i.e., Clopidogrel hydrogen sulfate amorphous was measured primarily by DSC.
Characterization of amorphous form by DSC is quick and easy. The pure crystalline
forms of both the drugs were tested at first by DSC (see Figure 6.1). The crystalline
Clopidogrel hydrogen sulfate melted at 176.11o C. The Heat of Fusion was 81.33 J/g.
The samples prepared in ethanol, dried in vacuum were transformed to the amorphous
form. The characteristic melting point disappeared completely from the DSC curves of
the amorphous form. The glass transition temperature is a very important parameter for
amorphous materials. Approximately for the all the amorphous materials the Tg is
usually observed at 2/3 to 4/5 of Tm (in Kelvin) [6]. The melting point of crystalline
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Clopidogrel hydrogen sulfate is 176.11oC (449.11 K). Accordingly, the expected Tg for
Clopidogrel hydrogen sulfate is the temperature interval of 26.4 - 86.2 oC.
The DSC curve reveals all the structural changes accompanied by enthalpy
changes. The Tg is usually indicated by a step in the DSC curve. However, for the first
heat cycle of Clopidogrel hydrogen sulfate Tg could not be detected. The Tg was
observed or appeared in the 2nd heating curve of DSC (see Figure 6.2). The resulting Tg
was at 89o C and the ΔCp at Tg was 0.256 J/g/C.
Quinapril.HCl amorphous sample was prepared by solvent evaporation method.
The solvent used to prepare the amorphous sample was dichloromethane. DSC was used
to determine the physical properties i.e., the glass transition temperature. For the
amorphous Quinapril.HCl the Tg was observed at 79 – 85 oC for the first and the second
heating cycle respectively. The melting point of crystalline Quinapril.HCl was 104 oC
and Heat of fusion = 25J/g. The other drugs analyzed by the DSC heating and cooling
cycles are listed in the Table 5.
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Table 5
Summary of DSC heat-cool method for all the drugs studied
Drugs
Lidocaine.HCl

Tm oC
79

Heat of Fusion

Heat of crystallization

ΔHf (J/g)

ΔHc (J/g)

201

Tg = 17oC

% Crystalline

% Amorphous

Comments

-

-

Amorphous
Semicrystalline

Sulfapyridine

192

174

57, Tg = 61-62oC

33

67

&Amorphous
(2nd Heat Cycle)

130

Quetiapine Fumarate

173

124

Tg = 44-49oC

-

-

Amorphous

Indomethacin

155

127

Tg = 42-47 oC

-

-

Amorphous

-

-

Amorphous

-

-

Amorphous

-

-

Amorphous

1st run Tg = 79 oC &
Quinapril.HCl

104

25

2nd run Tg = 85oC
2nd Heating

Clopidogrel hydrogen sulfate

179

81

Procainamide.HCl

169

83

Tg = 89 oC
Tg = 47 oC

6.3.3 Powder x-ray diffraction (PXRD) analysis.
6.3.3.1 Methodology. X-ray Diffraction Analysis (XRD) is a structural tool to
identify APIs based on their molecular structure. Each drug has its own unique crystal
structure. If single crystal diffraction data is appropriately available the exact space group
structure can be determined clearly distinguishing it from most other structures. The
complex structure of pure drugs yields to an API crystal system probably an
orthorhombic, monoclinic or triclinic system. Most drugs analyzed by Wide Angle XRD
(WAXRD) can be viewed as multiple sharp intense peaks (half peak maxima typically
0.3o 2Θ) delineating their highly crystallinity nature. Contrary to the multiple sharp peaks
are the broad XRD bands (half maxima of 5-10o 2Θ) typical of amorphous materials.
Therefore, a sharp peak spectrum is a crystalline material and a broad diffuse peak
spectrum is an amorphous material.
All drugs examined by PXRD were first evaluated by DEA and then sampled for
PXRD.
6.3.3.2 Confirmation of Clopidogrel hydrogen sulfate and Quinapril.HCl
amorphous form by PXRD. The Clopidogrel hydrogen sulfate (CHS) and Quinapril.HCl
(Q.HCl) amorphous samples were tested by PXRD measurement. Diffractograms are can
be seen in (Figure 6.5) and (Figure 6.6) respectively. The investigation supported the
DSC results throughout for both Clopidogrel hydrogen sulfate and Quinapril.HCl. Figure
6.5 shows that the products prepared with ethanol for Clopidogrel hydrogen sulfate and
dichloromethane for Quinapril.HCl (see Figure 6.6) were converted to the amorphous
form, because the peaks disappeared from the diffractograms, and the spectra became
smooth. The DSC and the PXRD results suggested that samples prepared by solvent
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evaporation method for both the crystalline drugs i.e., CHS and Q.HCl were transformed
to the amorphous form.

Figure 6.5. Clopidogrel hydrogen sulfate samples measured by PXRD. (A) Crystalline form, (B) Amorphous sample
prepared with ethanol, dried under vacuum, (C) ICDD diffractogram of Clopidogrel hydrogen sulfate (bottom curve)

Figure 6.6. PXRD diffractograms of different batches of Quinapril.HCl amorphous forms. Amorphous samples
prepared with dichloromethane, dried under vacuum
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Indomethacin was initially crystalline and after either quench cooling or heating it
in the DEA and cooling to room temperature became amorphous. This behavior was also
observed in the diffractogram of the amorphous Indomethacin with broad diffuse XRD
bands. The diffractograms of pure crystalline and amorphous forms of Indomethacin is
shown in Figure 6.7. The indomethacin diffractogram shows that the sample that was
heated in the DEA was amorphous, because the peaks disappeared from the
diffractograms of the amorphous Indomethacin sample, and the spectra became smooth.
Likewise, Lidocaine.HCl, Quetiapine fumarate, Sulfapyridine (Figure 6.8), Quinapril.HCl
and Clopidogrel hydrogen sulfate all became totally amorphous after the DEA first run.
Also, PXRD analysis aided the determination of the amorphous/crystalline form whether
it was a surface vs. bulk identification by DEA activation energy method.

Figure 6.7. PXRD diffractograms of Indomethacin Crystalline and Amorphous forms. Amorphous sample analyzed on
DEA, Bottom curve (ICDD)
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Figure 6. 8. PXRD of Sulfapyridine Crystalline Form and DEA amorphous form, bottom curve (ICDD)

The summary of all the drugs, their identity (ICDD), distribution of crystalline peaks and
amorphous bands is elucidated in Table 6.

134

Table 6
Summary of all the drugs, their identity (ICDD), distribution of crystalline peaks and
amorphous bands
PXRD Peak Values 2 Θ / Cu Kα Radiation
Identity
Drugs

Crystalline Peaks

Amorphous Bands

ICDD
16, 21,
Lidocaine.HCl

Yes

10

12

15

17

25

37

50

16

21

28

45

16

22

45

28

46

25, 27
16, 20,
Sulfapyridine

Yes

11

12

15

22,23,24,
25, 28

Quetiapine Fumarate

21, 22,
Yes

15

16

20

(Seroquel) ®

23, 25
21, 24,

Procainamide. HCl

Yes

16

17

19

26, 29,
30
19, 21,

Clopidogrel
Yes

13

15

18

23, 24,

19

26

45

57

hydrogen sulfate
25
Quinapril.HCl

18, 22,
Yes

8

12

14

(Accupril)®

18

58

23, 25
22, 27,

Indomethacin

Yes

11

17

20

22
29, 31
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29

50

6.3.4 Scanning electron microscopy study.
6.3.4.1 Clopidogrel Hydrogen Sulfate. SEM photomicrographs obtained for a
pure crystalline form of Clopidogrel Hydrogen Sulfate (CHS) and an amorphous form of
CHS are shown in (Figure 6.9 and Figure 6.10) in selected magnifications. From the
photomicrograph of pure drug CHS; it is clear that the drug was present as irregularly
shaped beads and aggregate structures confirming the crystal nature of the material as
seen by DEA, DSC, PXRD data analyses.

Figure 6.9. SEM photomicrographs of pure crystalline drug Clopidogrel Hydrogen Sulfate at (a) 75X (top left); (b)
300X (top right) and (c) 1080X (bottom); 15 KV

The CHS amorphous form by SEM was identified as a flexible soft structure and
as layered plates or a round structure as soft scales (see Figure 6.10). The DSC and DEA
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as well as PXRD analysis of the CHS amorphous material correlates with the SEM
images.

Figure 6.10. SEM photomicrographs of amorphous forms of Clopidogrel Hydrogen Sulfate at (a) 89X (top left); (b)
102X (top right) and (c) 161X (bottom); 15 KV

6.3.4.2 Quinapril.HCl . SEM photomicrographs obtained for pure crystalline
forms of Quinapril.HCl (Q.HCl) and an amorphous form of Q.HCl are shown in (Figure
6.11 and Figure 6.12) in selected magnifications. From the photomicrographs of pure
drug Q.HCl; it is clear that the drug was present as a rod-like structure (1260X),
overlayed rods (200X) and an aggregate like structure at 100X. SEM photomicrographs
of the amorphous forms of Quinapril.HCl are viewed in Figure 6.12. The droplet-like
structures were apparently amorphous and underwent fluid flow.
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Figure 6.11. SEM photomicrographs of pure crystalline drug Quinapril.HCl at (a) 1260X (top left); (b) 200X (top
right) and (c) 100X (bottom); 15 KV

Figure 6.12. SEM photomicrographs of amorphous forms Quinapril.HCl at (a) 160X (top left); (b) 304X (top right)
and (c) 565X (bottom); 15 KV
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6.3.4.4 Quetiapine fumarate (Seroquel). SEM photomicrographs obtained for
pure crystalline form of Quetiapine Fumarate (Seroquel) and an amorphous form of
Quetiapine Fumarate (Seroquel) are shown in (Figure 6.13 and Figure 6.14) at selected
magnifications. From the photomicrographs of pure crystalline drug we can clearly
differentiate the amorphous form of the drug, where the structures are smooth, and no
distinct edges as well as appeared to have smooth surfaces.

Figure 6.13. SEM photomicrographs of pure crystalline drug Quetiapine Fumarate (Seroquel) at (a) 342X (top left);
(b) 915X (top right) and (c) 1100X (bottom); 10 KV
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Figure 6.14. SEM photomicrographs of amorphous form Quetiapine Fumarate (Seroquel) at (a) 25X (top left); (b) 50X
(top right) and (c) 70X (bottom); 10 KV

6.3.4.4 Sulfapyridine. SEM photomicrographs obtained for pure crystalline form
of Sulfapyridine and an amorphous form of Sulfapyridine are shown in (Figure 6.15) in
selected magnifications. From the photomicrograph of pure drug sulfapyridine it was
present as triangular crystals and the amorphous form was a block of the material with
surface fragments.
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Figure 6.15. SEM photomicrographs of pure crystalline drug Sulfapyridine and amorphous drug Sulfapyridine (a)
165X (Left, Crystalline Solid); (b) 304X (Right, Amorphous); 15 KV

6.3.4.5. Lidocaine.HCl. SEM photomicrographs obtained for pure crystalline
forms of Lidocaine.HCl are shown in (Figure 6.16) in selected magnifications. From the
photomicrograph of pure drug Lidocaine.HCl it is clear that the drug had geometric
shapes as plates and rods. The amorphous form of this drug was hygroscopic resulting in
a rubbery sticky structure. This was not amenable for SEM analysis. This amorphous
compound was analyzed by DEA.

Figure 6.16. SEM photomicrographs of pure crystalline Lidocaine.HCl (a) 100X (Left); (b) 200X (Right); 10 KV
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6.4 Conclusions
We were successful in establishing new DEA analytical methods to determine the
crystalline and amorphous content of drugs. i.e., the two DEA methods, the activation
energy method, as well as, the empirical method agreed with a correlation coefficient of
0.96. This protocol was additionally validated by DSC studies. DSC Analysis verified the
presence of amorphous and crystalline material based on changes in the heat of fusion
and the appearance of an amorphous Tg. PXRD succinctly separated the amorphous and
crystalline materials based on the multiple sharp and narrow peaks for crystalline
materials and exceptionally broad bands for the amorphous materials. SEM analysis
revealed softening and rounding on edges of amorphous materials while not changing
those images of crystalline structure.
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